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ABSTRACT OF THE DISSERTATION 
Mechanisms of G Protein Regulation by RGS Proteins and Small Molecule Inhibitors 
by 
Stanley Michinobu Kanai 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular and Cellular Biology 
Washington University in St. Louis, 2017 
Professor Kendall J. Blumer, Chairperson 
G protein coupled receptors transduce diverse extracellular signals like hormones, 
neurotransmitters, and photons to specific cellular responses through heterotrimeric G proteins. 
G proteins activate numerous effectors and signal transduction pathways, and therefore the 
regulation of G proteins is crucial for faithful propagation of specific cellular and physiological 
responses. A better understanding of the mechanisms that regulate G proteins should provide 
new insight into signaling pathways that govern healthy and disease states, and also provide 
opportunities for discovery of novel therapeutic targets.   
Regulator of G protein signaling (RGS) proteins are crucial regulators of G proteins, for 
they control amplitude and duration of G protein signaling responses.  RGS2 is particularly 
important because it is associated with many physiological and disease processes.  A key concept 
that has emerged is that physiological and disease processes are extremely sensitive to even 
modest changes in RGS2 expression levels.  The goals of this dissertation were to investigate the 
mechanism that controls RGS2 levels and to determine how dynamic RGS2 levels affect GPCR 
signaling. The particular focus was on the ubiquitin proteasome pathway (UPP), which is one of 
the key mechanisms that control RGS2 expression levels.  Rather than looking for components 
 viii 
 
of the UPP that recognize and degrade RGS2, a comprehensive analysis was performed on the 
RGS2 N-terminal domain to identify signals required for degradation.  This analysis revealed a 
novel bipartite hydrophobic motif that is required for degradation.  Intriguingly, deletion of these 
hydrophobic motifs did not abrogate binding with E3 ligases associated with RGS2 degradation, 
suggesting additional mechanisms are involved.   The effect of UPP mediated degradation of 
RGS2 on regulation of GPCR signaling was also explored.  Using a cell based, kinetically 
resolved, GPCR reporter assay, it was demonstrated that proteasome degradation of RGS2 
dynamically regulates GPCR signaling, influencing both agonist efficacy and the rate of receptor 
resensitization.   
G protein signaling pathways also can be modulated by small molecule inhibitors.  YM-
254890 and FR900359 are a class of small molecule inhibitors for G proteins that are selective 
and cell permeable.  They are promising research tools and leads for therapeutic agents, but the 
exact molecular mechanism of action of these inhibitors is not known.  The second part of the 
dissertation describes early stages of a study that aims to elucidate the mechanism of action of 
YM and FR.   Preliminary results that support an allosteric model of inhibition are reported, 
followed by a discussion of future work that will further test this model.  
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Chapter 1 
 
 Introduction 
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G protein coupled receptors and heterotrimer G proteins 
Multicellular organisms detect and adapt to environmental cues using cell surface 
receptors.  In humans, G protein coupled receptors (GPCR) comprise the largest family of cell 
surface receptors, with over 800 encoded in the genome (1).  GPCRs are widely expressed and 
are able to detect a broad spectrum of signals such as photons, hormones, peptides, and 
neurotransmitters, and they are fundamental to many physiological and disease processes.  
Accordingly, ~30% of drugs target GPCRs (2). 
GPCRs convert extracellular cues to intracellular signaling responses through 
heterotrimeric G proteins – the principal signal transducers that activate downstream effectors 
such as enzymes, kinases, and ion channels (1).  Heterotrimeric G proteins are composed of three 
subunits called α, β, and γ, and they serve as timed molecular switches that cycle “on” and “off” 
depending on the guanine nucleotide binding state (Figure 1.1).  In the “off” state, the Gα subunit 
is bound to GDP and forms a complex with the Gβγ heterodimer.  G protein signaling is turned 
“on” by a ligand activated GPCR that stimulates the Gα subunit to release GDP and bind to GTP.  
GTP binding induces allosteric changes that cause Gα and Gβγ to dissociate and activate their 
respective signaling effectors. G protein signaling eventually turns “off” when Gα hydrolyzes 
GTP to GDP to reform the Gαβγ heterotrimer (3).  The intrinsic rate of GTP hydrolysis is slow, 
and many biological processes like vision require faster rates of hydrolysis (4).  For these 
processes, the rate of GTP hydrolysis is accelerated by a family of Regulator of G protein 
signaling (RGS) proteins (5, 6).   
15 different Gα subunits and 5 Gβ and 13 Gγ subtypes form in many combinations to 
create heterotrimeric G proteins that elicit diverse signaling pathways (7–9) (Figure 1.2).  The 
Gα subunits are subdivided into four groups – Gαs, Gαi/o, Gαq/11, and Gα12/13 – based on 
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similarities in sequence and the general pathways they activate: Gαs generates cyclic AMP 
(cAMP) through adenylyl cyclase (AC) activation, Gαi/o inhibits adenylyl cyclase activity,   
Gαq/11 evokes calcium flux through phospholipase Cβ (PLC) activation, and Gα12/13 activates 
Rho family GTPases through RhoGEFs.  Gβ and Gγ subtypes can dimerize in many 
combinations, and as heterodimers exert a wide range of effects on ion channels and isoforms of 
PLC and AC (10).   
GPCR targeted therapies are commonly used because GPCRs are the gatekeepers of G 
protein signaling pathways that underlie many disease processes.  However, this strategy can be 
ineffective in cases where diseases are driven by multiple GPCRs that activate a common G 
protein signaling pathway.  Furthermore, GPCR targeted therapies are inappropriate for diseases 
driven by mutations that cause constitutive G protein activity independent of GPCRs (11, 12).  
Another complexity of GPCR and G protein signaling that blunts the use of GPCR targeted 
therapies is that a particular GPCR can couple to one or more class of Gα subunits; therefore, 
targeting such a GPCR can silence signaling pathways not related to disease processes and have 
off-target effects (7).  To circumvent the limitations of GPCR targeted therapies, many have 
sought to develop methods to directly target and modulate G proteins.    
Gaining a better understanding of cellular mechanisms that regulate G protein activity 
should provide insight into disease mechanisms as well as novel strategies for therapeutic 
targeting of G protein signaling pathways.   The overarching goal of this dissertation was to 
investigate mechanisms that regulate G protein signaling.  The first part of this dissertation aims 
to investigate the mechanism by which a negative regulator of G proteins, RGS2, is degraded by 
the ubiquitin proteasome pathway.  Furthermore, how proteasome degradation of RGS2 affects 
regulation of GPCR signaling is examined.  The second part of the dissertation describes early 
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stages of a study aimed towards elucidating the molecular mechanism by which a class of small 
molecule inhibitors allosterically block G protein activation.   
 
Introduction to Chapter 2: Agonist efficacy and resensitization in Gq-
mediated GPCR signaling are regulated by proteolytic degradation of 
Regulator of G Protein Signaling 2 
 
History and background of RGS proteins  
RGS proteins were first identified in yeast (Saccharomyces cerevisiae) and nematodes 
(Caenorhabditis elegans) as Sst2 and EGL-10, respectively (13, 14).  They were required for 
negative regulation of G protein signaling, but their exact biochemical properties were unknown.  
It was soon discovered there were a number of mammalian proteins with similar sequence and 
function to Sst2 and EGL-10, and their identities as RGS proteins were determined as they were 
biochemically defined as GTPase activating proteins (GAP) that selectively bind to the active 
state of Gα to accelerate GTP hydrolysis (15–20).   
There are ~30 members in the mammalian family of RGS proteins, and they are defined 
by the conserved RGS domain (Figure 1.3) (21).  Most RGS proteins function as GAPs towards 
Gαi/o or Gαq/11, but some have additional regulatory functions that arise in part from their 
structural diversity. For example, the C/R7, D/R12, E/RA, F/GEF, G/GRK, and H/SNX class are 
large multi-domain proteins that confer regulatory functions that extend beyond GPCR and G 
protein signaling pathways.  In contrast, the A/RZ and B/R4 class are relatively smaller with 
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simple domain architectures. With the exception of RGS3, members of this class are composed 
simply of an RGS domain flanked by a short N-terminal tail.  
 
RGS proteins as drug targets 
The small RGS proteins are particularly intriguing because despite their simple structure, 
some exhibit preferential activity towards specific GPCR and G protein signaling pathways 
(Figure 1.4).  For example, due to slight differences in the RGS domains of RGS2 and RGS4, 
RGS2 exhibits preferential GAP activity towards Gαq over Gαi, whereas RGS4 exhibits GAP 
activity for both (22–24).  Preference can also arise from N-terminal domains that confer 
selective interactions with GPCRs (25).  Gαq coupled Muscarinic receptors (but not Gαi coupled 
receptors) and α1-Adrenergic receptor preferentially bind the N-terminal domain of RGS2 over 
closely related B/R4 family members RGS1, RGS4, and RGS16 (26, 27).   
Because RGS proteins exhibit preferential activity towards specific G protein and GPCR 
signaling pathways, they have drawn significant interest as potential drug targets (5, 28, 29).  
RGS2 is a particularly promising drug target because it is linked to many disease processes like 
anxiety (30–32), hypertension (33–35), heart failure (36–38), and some cancers (39).  A key 
emerging concept is that RGS2 function is sensitive even to modest changes in expression levels, 
and one of the major processes that control RGS2 levels is the ubiquitin proteasome pathway 
(UPP) (40–42).  Therefore, many efforts have gone towards uncovering the UPP mediated 
degradation mechanism for RGS2 to gain insight into pathogenesis and novel drug targets (40–
44).   
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Ubiquitin proteasome pathway as a source of drug targets  
The UPP determines the half-life of many signaling and regulatory proteins and is crucial 
for coordinating many cellular processes like cell cycle progression and immune cell function.  
Substrates are recognized and degraded by the UPP in a highly specific manner, where substrates 
are covalently modified with poly-ubiquitin chains and then sent to the 26S proteasome for 
degradation (45) (Figure 1.5A).  Substrate polyubiquitination occurs in a general three-step 
process that is coordinated by three enzymes, E1, E2, and E3.  E1 is a ubiquitin activating 
enzyme that “activates” free ubiquitin molecules to a high energy thiol ester intermediate in an 
ATP dependent reaction.  The E2 conjugating enzyme accepts the “activated” ubiquitin and then 
ubiquitin-conjugates the substrate protein bound to the E3 ubiquitin ligase.   
Substrate recognition by an E3 ligase is specific, and it is determined by unique 
degradation signals that exist in a variety of forms like phosphorylated motifs, primary sequences 
enriched in particular residues, secondary or tertiary structures, misfolded or unstructured 
domains, or simply a destabilizing N-terminal amino acid  (46).  It is hypothesized that any 
particular substrate of the UPP is degraded by a dedicated set of enzymes assembled from over a 
hundred E2s, over a thousand E3s, and countless other adaptor proteins and substrate recognition 
modules encoded in the genome (47) (Figure 1.5B).  Due to the sheer number of unique 
components potentially involved in the degradation of any particular substrate, the UPP offers a 
highly promising trove of drug targets (48).  
 
RGS2 degradation mechanism 
Many have sought to elucidate the RGS2 degradation mechanism to better understand the 
pathways underlying disease processes.  It also has been motivated by the promise that it will 
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reveal unique drug targets that can selectively inhibit RGS2 degradation.  Despite efforts to 
characterize the RGS2 degradation mechanism the picture is still incomplete (41, 42).  The 
leading hypothesis is that RGS2 is degraded by the N-end rule pathway of the UPP, which 
utilizes the identity of the N-terminal residue for substrate recognition. The N-terminal residue of 
RGS2, glutamine at position 2, is a predicted degradation signal, or N-degron, for the N-end rule 
pathway.  N-degrons are categorized in a hierarchy of primary, secondary, or tertiary degradation 
signals.  Primary N-degrons are directly recognized by E3 ligases (Figure 1.6).  Secondary and 
tertiary N-degrons require modifications by oxidation or enzymatic reactions by amino peptidase 
(MetAP1), arginyl transferase (ATE1), or N-terminal acetylase (NAA60) before recognition by 
E3 ligases.  Based on these set of rules, Park et al. proposed that RGS2 is co-translationally 
acetylated at the N-terminal methionine by NAA60 and then degraded by the TEB4(MARCHVI) 
E3 ligase (42).   
However, several lines of evidence suggest additional mechanisms may be involved.  For 
example, the knockdown of ATE1, a key enzyme in the N-end rule pathway, does not stabilize 
RGS2 (41).  An RGS2 mutant Q2R that has lost the predicted N-degron is not proteolytically 
stabilized (40).  Furthermore, the CUL4B-DDB1-FBXO44 E3 ligase, which is not associated 
with the N-end rule pathway, is necessary for RGS2 degradation (41).  Taken together, these 
observations suggest our understanding of the RGS2 degradation mechanism is incomplete.  
Therefore, it was hypothesized that additional mechanisms are responsible for the degradation of 
RGS2 and is explored further in this dissertation.   
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Proteasome degradation of RGS2 and GPCR regulation 
How UPP mediated degradation of RGS2 affects GPCR signaling also is not well 
understood.  For example, RGS2-Q2L, a rare missense mutation found in patients with 
hypertension, exhibits rapid UPP dependent degradation, lower steady state expression levels, 
and impaired ability to inhibit angiotensin II mediated IP3 production, but whether this was due 
to proteasome degradation was not demonstrated (34, 40).  The stabilization of RGS2 by TEB4 
knockdown resulted in increased inhibition of ERK phosphorylation; however, whether this was 
a direct effect on stabilizing RGS2 as opposed to other signaling molecules was not established 
(42).   
Furthermore, the regulatory mechanism of RGS2 mRNA expression suggests proteasome 
degradation of RGS2 may play a vital role in controlling GPCR signaling dynamics like 
desensitization and resensitization.  In many cell types and tissues, RGS2 mRNA is rapidly 
upregulated in response to receptor activation by Gs and Gq agonists, and it is thought to be 
involved in a negative feedback mechanism that serves to attenuate or desensitize GPCR 
signaling (6).  Because the UPP degrades RGS2 rapidly with a half-life of ~30 minutes (41, 42), 
this suggests that the UPP restores agonist sensitivity by rapidly degrading RGS2.  The role of 
proteasome degradation of RGS2 on GPCR signaling dynamics, however, has never been 
studied. Therefore, the second goal was to determine how proteasome mediated degradation of 
RGS2 affects regulation of GPCR signaling.  
The goals for this part of the dissertation were twofold: 1) to perform a comprehensive 
analysis of the RGS2 degradation mechanism and 2) to investigate how proteasome mediated 
degradation of RGS2 affects GPCR regulation.   
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Introduction to Chapter 3: Investigation of the GDI mechanism for YM-
254890 and FR900359 
 
History of G protein inhibitors 
One of the first identified selective G protein inhibitors was pertussis toxin (PTX), a 
virulence factor from Bordetella pertussis, a bacterial strain responsible for whooping cough 
disease.  PTX catalyzes ADP ribosylation of Gαi/o subunits on a C-terminal cysteine residue, 
which decouples Gαi/o from its receptor and renders it insensitive to GPCR activity (49).  PTX 
was initially used to identify the PTX sensitive class of Gαi/o alpha subunits (50), and since then 
it has been extensively used as a research tool to deconvolute G protein signaling pathways.   
Over the last several decades, selective inhibitors of G proteins have been sought for 
research and clinical use.   Increasing understanding of the structural features and mechanism of 
G protein activation have revealed surfaces and catalytic regions of Gα subunits that can be 
exploited as drug targets (11, 51).  There are now a variety of small molecules and peptides that 
can inhibit G proteins, but all lack the selectivity and pharmacokinetic properties desired for 
research and clinical use (11).  Nevertheless, these compounds have illuminated mechanisms of 
G protein inhibition.  
Suramin is a small organic molecule that was used to treat African Sleeping Sickness, but 
it was discovered that it also can selectively inhibit G protein activation.  Suramin and its 
derivatives were found to inhibit nucleotide exchange, the rate limiting step of G protein 
activation, with some preference for Gα subtypes (52–54).  It appears to inhibit G protein 
activation by disrupting both GPCR-G protein coupling and G protein-effector interactions. The 
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use of suramin and its derivatives, however, is limited to in vitro testing because it is membrane 
impermeable.  BIM-46174 is another organic small molecule inhibitor for G proteins that works 
by preventing GDP release.  It is membrane permeable unlike suramin but lacks G protein 
selectivity (55, 56).  Although these drugs serve as promising starting points for designing 
derivatives with improved selectivity and membrane permeability, the lack of structural 
information on how these compounds interact with G proteins have hindered such endeavors.  
Peptide based inhibitors modeled after known cellular modulators of effector binding 
sites for G proteins have also been successfully developed.  For example, the GoLoco motif is an 
evolutionarily conserved α-helical structure found in regulatory proteins such as RSG12 and 
AGS3 that is a selective negative regulator of Gαi/o but can also discriminate between Gαi 
subunits (57).  A peptide bearing only the GoLoco motif  is sufficient to bind Gαi and interfere 
with inter-domain opening and GDP release (58).  Effector binding sites on Gα can also be 
targeted by peptides.  For example, a peptide was developed to bind to the well characterized 
interaction interface of Gαq and PLCβ, and it was shown to displace PLCβ by competitive 
inhibition (59).  This peptide has been proven to work in vivo, as it inhibits Gαq driven processes 
when injected in mouse brains.    Ultimately, however, the challenge with peptide based 
inhibitors is that delivery to target cells and organs is difficult due to poor stability and 
membrane permeability, and thus applications are largely limited to in vitro assays  
 
YM-254890 and FR-900359: novel class of G protein inhibitors 
YM-254890(YM) and FR900359(FR) are natural compounds that are nearly identical in 
structure (60, 61).  They are cell permeable and selectively inhibit Gαq, Gα11, and Gα14, but not 
Gα16 or the Gαi/o, Gαs, or Gα12/13 family of subunits.  YM/FR function as guanine nucleotide 
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dissociation inhibitors (GDI), but the molecular basis of the GDI activity is still unclear (60, 62).  
A co-crystal structure of YM-Gq has provided a snapshot of the interactions between YM and 
Gq (62).  Notably,   YM binds to a hydrophobic pocket that is present but in diverged form 
across all classes of Gα subunits.  Furthermore, mutational analysis showed that YM selectivity 
is determined in part by residues unique to the Gq/11 class of α subunits.  Based on this structure 
and other observations, it has been hypothesized that YM/FR inhibits GDP release by an 
allosteric mechanism, but the exact molecular mechanism is still undefined. 
The goal of this part of this dissertation is to highlight key observations that form the 
foundation for the hypothesis that YM/FR inhibits GDP release by allosteric inhibition of the 
universal G protein activation mechanism.  Furthermore, preliminary data that support this 
hypothesis is presented, followed by a discussion of future work that will further test this model.  
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FIGURES 
 
FIGURE 1.1.  Heterotrimeric G protein activation cycle (taken from (3)) 
An agonist bound GPCR stimulates Gα to release GDP.  The Gα subunit then binds GTP 
because cytoplasmic concentrations of GTP are higher than GDP. GTP binding causes 
conformational changes in the Gα subunit that lead to dissociation from the Gβγ subunit.  Free 
Gα and Gβγ heterodimers then activate their respective effectors.  G protein signaling terminates 
when the Gα subunit hydrolyses GTP to GDP with its intrinsic GTPase activity, which causes 
the re-formation of the Gαβγ heterotrimer.  The duration of Gα signaling is determined by the 
rate of intrinsic GTPase activity but is typically accelerated by the presence of RGS proteins. 
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FIGURE 1.2.  Diversity of G protein signaling (taken from (63)) 
Gα subunits are subdivided into four categories based on the general effector and signaling 
pathways they activate.  Gs activates adenylyl cyclase, which stimulates production of second 
messenger cAMP.  cAMP activates protein kinase A(PKA), which phosphorylates a diverse 
array of substrates. Gi/o antagonizes Gs by inhibiting adenylyl cyclase.  The Gi/o is the only 
class that is sensitive to pertussis toxin (PTX). Gq/11 activates phospholipase Cβ (PLCβ), which 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and 
inositol 1,4,5-triphosphpate (IP3).  DAG activates protein kinase C, and IP3 stimulates release of 
intracellular calcium stores. G12/13 class activates RhoGEF, which subsequently activates the 
small GTPase RhoA.  The βγ subunits also activate effectors such as inward rectifying potassium 
channels and PLCβ.    
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FIGURE 1.3.  Mammalian family of RGS proteins (taken from (21)) 
Members of this family are defined by the conserved RGS domain.  RGS proteins are 
structurally diverse and are subdivided based on similarity of sequence and domain architecture.  
RGS2 is a member of the B/R4 family and smaller relative to other RGS family members (with 
the exception of RGS3).  The domain architecture of B/R4 family members is also simple.  The 
RGS domain is flanked by a short N-terminal domain that contains a hydrophobic amphipathic 
α-helix flanking the RGS domain and a short C-terminal tail. A/RZ members are similar in 
structure, but they have an additional Cysteine string in the N-terminus.  In contrast, the other 
family members are large multidomain proteins, as highlighted by the C/R7, D/R12, E/RA, and 
F/RL families.    
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FIGURE 1.4.   RGS protein-targeted therapies can modulate specific G protein signaling 
pathways (taken from (5)) 
Modulation of specific RGS proteins can selectively activate therapeutically beneficial signaling 
pathways while avoiding adverse side effects.  For example, inhibition of RGS2 may selectively 
activate a branch of the muscarinic signaling pathway that enhances cognitive faculties for 
Alzheimers patients while avoiding bradycardia. Cholinergic agonists have the dual effect of 
enhancing cognitive abilities and causing bradycardia by activating Gq and Gi/o coupled 
cholinergic receptors, respectively.  Therefore, inhibition of RGS2, which is a negative regulator 
of Gq, could potentially have therapeutic benefits.  
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FIGURE 1.5.  Ubiquitin proteasome pathway and potential drug targets (A taken from (47), B 
adapted from (48)) 
(A) A schematic of the steps involved in the ubiquitin proteasome pathway. (B) Cartoon 
represents the hierarchy of components in the UPP and the vast number and diversity of 
components that determine substrate specificity.  The mammalian genome encodes two E1 
activating enzymes and hundreds of E2 conjugating and E3 ubiquitin ligase enzymes.   Because 
there are potentially hundreds and thousands of components involved in substrate recognition 
and degradation, the UPP is an attractive source for unique drug targets.  
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FIGURE 1.6.  Arg/N-end rule, Ac/N-end rule pathway (Taken from (64)) 
Substrates of the N-end rule pathway are degraded by a hierarchy of N-terminal degradation 
signals (N-degrons). (A) Primary N-degrons are directly recognized by the UBR class of E3 
ligases. Secondary and tertiary N-degrons are transformed to primary N-degrons through 
enzymatic reactions (or oxidation in the case of N-terminal Cysteine). (B) Select residues are 
transformed into N-degrons for the Ac/N-end rule pathway by N-terminal acetylation.    
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ABSTRACT  
Regulator of G protein signaling 2 (RGS2) is a GTPase activating protein (GAP) that controls 
the kinetics and amplitude of G protein signaling responses involved in many physiological and 
disease processes. These processes are extremely sensitive even to modest changes in RGS2 
expression levels; therefore, understanding the mechanisms that control RGS2 expression may 
provide valuable insight into disease pathogenesis and novel therapeutic targets.  A major 
cellular process that regulates RGS2 expression is the ubiquitin proteasome pathway (UPP).  To 
date, several mechanisms of UPP mediated degradation have been proposed, but many 
conflicting observations suggest that additional mechanisms are involved.  Therefore, a goal of 
this study was to determine whether additional mechanisms are involved in RGS2 degradation.  
Rather than to look for components of the degradation machinery, the N-terminal domain of 
RGS2 was comprehensively analyzed to determine whether additional degradation signals exist.  
This analysis revealed a novel bipartite hydrophobic motif that is necessary for degradation.  
Intriguingly, deletion of the hydrophobic motifs did not abrogate interactions with TEB4 or 
CUL4B-DDB1-FBXO44 E3 ligases, which were reported in previous studies to be necessary for 
RGS2 degradation. A second goal of this study was to investigate how the proteasome mediated 
degradation of RGS2 affects the regulation of Gq-coupled receptor signaling. Using 
proteolytically insensitive or hypersensitive mutants identified in the initial analysis, it was 
demonstrated that proteasome degradation dynamically regulates GPCR signaling by controlling 
agonist efficacy and the rate of agonist responsiveness (resensitization).  These findings extend 
our current understanding of the RGS2 degradation mechanism and demonstrate that proteasome 
mediated degradation of RGS2 dynamically regulates GPCR signaling. 
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INTRODUCTION  
Signal transduction by G protein coupled receptors (GPCRs) in mammalian cells is 
regulated by diverse mechanisms that determine agonist response amplitude (efficacy), kinetics, 
desensitization and resensitization, thereby providing novel drug targets to modulate GPCR 
signaling in many diseases (1). Among these regulatory mechanisms, those mediated by the 
regulator of G protein signaling (RGS) family of proteins have proved to be crucial as indicated 
by the diverse phenotypes of mice lacking certain RGS proteins or expressing RGS-insensitive G 
protein mutants (2, 3) and rare polymorphisms in human RGS-encoding genes (4–6).  These 
phenotypes are thought to occur because many RGS proteins are capable of regulating the 
amplitude and kinetics of GPCR signaling by functioning as GTPase-activating proteins (GAPs) 
for G protein α-subunits (7), and some RGS proteins can also affect cell signaling and other 
processes by GAP-independent mechanisms (8).   
Among >30 RGS proteins encoded by the human genome, RGS2 is of particular interest.  
RGS2 acts as a GAP preferentially for Gq/11-class α-subunits relative to Gi/o α subunits (9–12) 
and also has several GAP-independent functions (8, 13, 14).  RGS2 is expressed in many organs, 
tissues and cell types, and participates in diverse physiological and disease processes including T 
cell activation (15), blood pressure regulation (16–20), cardiac hypertrophy and heart failure 
(21–23), renal hemodynamics (20), anxiety (15, 24), and certain cancers (25).  
A key emerging concept is that physiological and disease processes are strikingly 
sensitive even to modest changes in RGS2 function or expression level.  For example, loss of just 
one RGS2 allele is sufficient to elevate blood pressure in mice (16), rare missense mutations that 
reduce RGS2 protein expression are associated with hypertension in humans (4, 5), and RGS2 
downregulation occurs in human hypertension (26). Furthermore, in several cell types and tissues 
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RGS2 mRNA expression is upregulated transiently in response to various stimuli, GPCR 
agonists, and second messengers as inducible feedback loops that attenuate or desensitize GPCR 
signaling or cross-regulate signaling by different classes of G proteins (12, 27–35).   
Such evidence has motivated efforts to identify mechanisms that regulate RGS2 
expression or function, which could provide new insight into disease pathogenesis or novel 
targets for therapeutic development. Among such mechanisms, proteolytic degradation of RGS2 
may be particularly important.  RGS2 protein half-life is short (~30 min) due to ubiquitin and 
proteasome-mediated proteolysis (36–38). Targeting this process has therapeutic potential 
because in mouse models cardiac glycosides, such as ouabain, inhibit RGS2 degradation and 
protect against cardiac injury in a RGS2-dependent manner (39).   
Mechanisms that mediate proteolytic degradation of RGS2 are complex. One mechanism 
is the acetylated N-end (Ac/N) rule pathway involving the N-recognin TEB4 (MARCH6), the N-
terminal acetylase Naa60, and the identity of the amino acid at position 2 in RGS2 (38). 
However, other mechanisms also have been implicated because RGS2 degradation depends on a 
ubiquitin E3 ligase complex (CUL4B, DDB1, FBXO44) unlinked to the N-end rule pathway 
(37). RGS2 degradation can be regulated by cardiac glycosides (39, 40), protein kinase C 
activators (41), or a cGMP-dependent protein kinase inhibitor (42). Whether these effects occur 
by targeting recognition of RGS2 by the Ac/N-end rule and/or CUL4B/DDB1/FBXO44-
dependent pathways is unknown. 
Less well understood is how proteolytic degradation of RGS2 affects GPCR signaling. 
Whereas a rapidly-proteolyzed hypertension-associated RGS2(Q2L) mutant exhibits reduced 
function (36), whether this effect occurs by proteolytic degradation or other mechanisms is 
unknown.  Similarly, although knockdown of Ac/N-end rule components stabilizes RGS2 and 
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enhances inhibition of Gq-mediated Erk activation (38), whether this effect occurs by inhibiting 
proteolytic degradation of RGS2 as opposed to other signaling molecules is unclear. Moreover, 
whereas knockdown of CUL4B/DBB1/FBXO44 complexes inhibits RGS2 degradation (37), its 
effect on GPCR signaling was not investigated. Lastly, whether RGS2 proteolysis regulates 
GPCR signaling amplitude, kinetics, desensitization or resensitization has not been studied. 
Here our goals were to determine how RGS2 is targeted for ubiquitin/proteasome-
mediated degradation and to establish how Gq-mediated GPCR signaling is regulated by RGS2 
proteolysis. Rather than knocking down components of the N-end rule or other pathways, which 
could have pleiotropic effects on cell signaling, we have used a structure-function approach to 
identify and characterize degradation signals in RGS2.  By analyzing RGS2 mutants that degrade 
faster or more slowly than the wild type protein, we have identified novel degradation signals 
and provided new insight into how proteolytic degradation of RGS2 regulates the amplitude and 
dynamics of Gq-mediated GPCR signaling. 
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RESULTS 
RGS2 degradation requires two internal motifs – Because N-terminal acetylation and the 
identity of the amino acid at position 2 in RGS2 are the only features shown thus far to affect 
proteolytic degradation of this protein, our first goal was to conduct a more comprehensive 
identification of motifs or domains that are necessary and sufficient for RGS2 proteolysis as a 
means of better understanding the mechanisms and functions of this process.  RGS2 is a 211-
residue protein that contains an ~80-residue N-terminal region, followed by the RGS domain that 
is necessary and sufficient for GAP activity, and a short C-terminal tail (Figure 2.1A). We began 
by studying the degradation rates of RGS2 translated from four previously identified alternative 
in-frame initiation sites at methionine 1, 5, 16 and 33 (M1, M5, M16, M33; Figure 2.1A and B 
(28, 43–45)) to explore the role of the N-terminal region. Which of these alternative translation 
products are expressed endogenously in cells or tissues remains unclear due to low expression, 
rapid degradation or limitations of antibodies used for immunoblotting.  Regardless, the N-end 
rule machinery is predicted to recognize each RGS2 alternative translation product due to the 
identity of the amino acid residue immediately following the initiating methionine (i.e. Q2, F6, 
D17, K34 (46)). To study RGS2 degradation, we tagged the protein at its C-terminus with 3 
copies of the FLAG epitope (RGS2(3XFLAG)), which  preserves function (see below). To 
simplify analysis, single translation products initiated only at M1, M5, M16 or M33 were 
produced by changing other in-frame methionine residues to leucine, a conservative substitution. 
Degradation rates of RGS2(3XFLAG) initiated at single translation start sites were determined 
by quantitative immunoblotting of transfected HEK293 cell lysates harvested over time after 
inhibiting new protein synthesis with cycloheximide (CHX; Figure 2.1C), and by pulse-chase 
labeling experiments (not shown). Results indicated that RGS2 initiated at M1 or M5 was 
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degraded much more rapidly than RGS2 initiated at M16 or 33 (Figure 2.1C and D), suggesting 
that an internal motif between M5 and M16 promotes RGS2 degradation. 
To test this hypothesis further, we generated small internal deletions in RGS2(3XFLAG) 
initiated at M1 (M1-RGS2(3XFLAG);  Figure 2.2A) and analyzed their effects on degradation 
rates following CHX treatment. Deletion of residues 5-9 impaired RGS2 degradation whereas 
removing residues 8-12 or 10-15 had insignificant effect (Figure 2.2B and E), suggesting that the 
former deletion disrupted an internal degradation-promoting motif.  This result also suggested 
that the N-terminal residues of RGS2 are not the sole determinants of proteolysis because the Δ5-
9 mutant still contains the glutamine residue at position 2 hypothesized to promote degradation 
of wild type RGS2 by the Ac/N-end rule machinery.  
Features of the degradation-promoting motif in residues 5-9 were identified by point 
mutagenesis of M1-RGS2(3XFLAG). Because this region lacks charged or polar residues, its 
hydrophobic character may be functionally important. Indeed, substituting residues 6 or 7 with 
an aspartic acid residue (Figure 2.2D) markedly impaired degradation of M1-RGS2(3XFLAG) 
(Figure 2.2E and F), whereas an aspartic acid substitution at position 9 had insignificant effect 
(Figure 2.2E and F).  In contrast, the specific amino acid sequence of this hydrophobic region 
was unimportant because scrambling its sequence (Figure 2.2G) did not affect degradation rate 
(Figure 2.2H and I). Therefore, degradation of RGS2 requires a motif composed of hydrophobic 
residues near the N-terminus. 
Whereas the preceding results indicated that proteolytic degradation of wild type RGS2 is 
not determined solely by the amino acid at position 2, degradation of the hypertension-associated 
missense mutant (RGS2-Q2L (4, 5, 47)) nevertheless may be determined mainly by this 
mechanism due to the presence of a destabilizing leucine residue at position 2. We tested this 
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hypothesis by determining the rate that M1-RGS2-Q2L(3XFLAG) is degraded in HEK293 cells 
when residues 5-9 were deleted or the hydrophobic character of this region was disrupted by an 
F6D substitution (Figure 2.3A). Results showed that the degradation of M1-RGS2-
Q2L(3XFLAG) is strikingly impaired by either the Δ5-9 or F6D mutation (Figure 2.2B and C), 
indicating that its proteolytic degradation also requires this internal hydrophobic motif. 
To determine whether this hydrophobic motif promotes degradation in vascular smooth 
muscle cells, where RGS2 regulates vascular reactivity (18, 42, 48), we analyzed steady state 
expression as an indicator of protein stability in transfected A7r5 cells (Figure 2.3D).  We found 
that the M1-RGS2-F6D(3XFLAG) mutant was expressed somewhat more highly than wild type 
M1-RGS2(3XFLAG).  Moreover, introducing the F6D substitution into the Q2L mutant form of 
M1-RGS2(3XFLAG) dramatically increased steady state expression relative to the Q2L-only 
control (Figure 2.3D). Control experiments showed that steady state expression of M1-
RGS2(FLAG) and M1-RGS2-Q2L(FLAG) in A7r5 cells is proteasome-dependent, as indicated 
by the effects of MG-132 (Figure 2.3D). Thus, the hydrophobic degradation-promoting motif 
proximal to the N-terminus functions in a non-cell type specific manner and determines the 
steady state expression level of RGS2. 
Although the preceding results indicated that a hydrophobic motif near the N-terminus is 
required for RGS2 degradation, the results of further experiments indicated that this motif is 
insufficient and instead cooperates with a second internal signal composed of an amphipathic α-
helix.  This conclusion was suggested initially by analyzing degradation of GFP fusion proteins 
bearing various regions of the RGS2 N-terminal domain (Figure 2.4).  Fusing the entire N-
terminal domain of RGS2 (residues 1-80) to GFP (Figure 2.4A) was sufficient to promote 
degradation relative to untagged GFP (Figure 2.4B-D).  In contrast, deleting residues 30-50 of 
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this RGS2-GFP fusion protein, which removes a previously described amphipathic α-helical 
region but preserves the N-terminal hydrophobic motif, strikingly impaired degradation (Figure 
2.4B-D), indicating that the hydrophobic N-terminal motif is insufficient to promote degradation. 
These results were extended by analyzing point mutations affecting the hydrophobic face of the 
amphipathic α-helical region of M1-RGS2(3XFLAG) (Figure 2.4E-H). Results showed that 
degradation the L45D or the L45D/L49D double mutant forms of M1-RGS2(3XFLAG) is 
markedly impaired (Figure 2.4G and H).  However, further results indicated that the amphipathic 
α-helical domain is insufficient to promote degradation because a GFP fusion protein bearing 
residues 16-80 of RGS2, which removes the N-terminal hydrophobic motif but preserves the 
amphipathic α-helical motif (Figure 2.4A), was as proteolytically stable as GFP (Figure 2.4C and 
D). Thus, RGS2 degradation requires two internal motifs apart from the residue at position 2: a 
hydrophobic region near the N-terminus and an amphipathic α-helix further downstream.   
RGS2 degradation determines the efficacy of a Gq-coupled GPCR agonist—With these 
RGS2 mutants in hand, we next developed a system to determine how degradation impacts the 
ability of RGS2 to regulate Gq-coupled GPCR signaling. In contrast to previously used signaling 
endpoint assays (Erk activation (38); inositol phosphate accumulation (36)), we used Ca
2+
 
signaling to provide a quantitative, kinetically resolved read out for determining how RGS2 
degradation impacts the amplitude or dynamics of agonist-evoked Gq signaling. For these 
purposes we used transfected Twitch-2B (49), a FRET reporter of Ca
2+
 signaling, to monitor 
agonist (carbachol) stimulation of Gq-coupled muscarinic receptors in HEK293 cells transfected 
with wild type or mutant forms of RGS2 that are degraded at different rates.   
First, we determined whether degradation sets steady state expression level of RGS2 and 
affects the ability of this protein to regulate Gq-coupled GPCR-evoked Ca
2+
 signaling.  To 
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analyze RGS2 mutants exhibiting different degradation rates, we chose not to study mutations 
affecting the amphipathic α-helical region because they abrogate plasma membrane targeting and 
function of RGS2; instead we studied mutations affecting the hydrophobic motif near the N-
terminus. We found that steady state expression levels of M1-RGS2(3XFLAG) and its F6D 
derivative are linearly dependent on the amount of transfected plasmid (Figure 2.5A and B).  
Expression of the Q2L derivative also increased with the amount of transfected plasmid (Figure 
2.5A) but below the linear range of detection. Next we compared carbachol-evoked Ca
2+
 
response in HEK293 cells lacking or expressing increasing levels of transfected wild type or 
mutant forms of M1-RGS2(3XFLAG).  In the absence of transfected RGS2, a maximal 
concentration of carbachol evoked a rapid, sustained Ca
2+
 response (Figure 2.5C).  In response to 
increasing levels of transfected wild type M1-RGS2(3XFLAG), agonist efficacy (maximal Ca
2+
 
response) diminished (Figure 2.5C and D). Expression of the unstable Q2L derivative also 
reduced agonist efficacy, but required ~2-fold more transfected plasmid to produce an equivalent 
inhibitory effect (Figure 2.5C and D).  Conversely, the slowly degraded F6D derivative required 
~3-fold less transfected plasmid relative to wild type RGS2 to elicit an equivalent inhibitory 
effect (Figure 2.5C and D).  Thus, the degradation rate of RGS2 correlated inversely with 
function as a regulator of agonist efficacy over at least a 12-fold range of steady state expression.   
RGS2 degradation facilitates resensitization of Gq-coupled GPCR signaling—RGS2 
mRNA expression in many cell types is upregulated strikingly and transiently in response to 
various GPCR agonists or other extracellular signals or second messengers, and then declines to 
baseline within ~1-2 h, suggesting that this process potentially functions as a transiently acting 
feedback loop that blunts, or desensitizes GPCR signaling. If so, proteolytic degradation could be 
important for determining not only peak RGS2 protein expression levels and the consequent 
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magnitude of signal attenuation or desensitization, as indicated above, but also how quickly cells 
resensitize or regain agonist responsiveness as RGS2 mRNA expression declines, thereby 
terminating the inhibitory feedback loop.  
We tested this hypothesis by adapting the Ca
2+
 signaling system described above to study 
how cells regain agonist responsiveness or resensitize over time after synthesis of M1-
RGS2(3XFLAG) is stopped by blocking new protein synthesis with CHX in the absence or 
presence of MG-132. This approach also was used to compare cells transfected with wild type, 
fast (Q2L) or slowly degrading (F6D) forms of M1-RGS2(3XFLAG). In each experiment, cells 
were treated for various periods of time with CHX and then stimulated with a maximal 
concentration of carbachol to determine whether agonist efficacy recovers after RGS2 synthesis 
stops and proteolysis proceeds. The dependence of “resensitization” (recovery of agonist 
efficacy) over time on proteasome-mediated degradation was determined by experiments in 
which cells were treated simultaneously with CHX and MG132 for various time periods, and 
then stimulated with agonist to assess Ca
2+
 responsiveness. Experiments using cells 
untransfected with RGS2 indicated that agonist efficacy changed insignificantly over 40 min 
after treatment with CHX in the absence or presence of MG-132 (Figure 2.6A and B), indicating 
that the functions of endogenously expressed signaling or regulatory proteins are unaffected 
during this time course by proteasome-mediated degradation.   
In contrast, clear evidence of proteasome-dependent resensitization was obtained with 
cells expressing M1-RGS2(3XFLAG).  These cells initially exhibited blunted agonist response, 
which recovered or resensitized significantly within 40 min after new protein synthesis was 
inhibited with CHX (Figure 2.6A and B). This recovery process was proteasome-dependent since 
it was blunted when cells were treated with CHX and MG-132 (Figure 2.6A and B), as expected 
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if it is due to RGS2 degradation.  Similarly, cells expressing the unstable RGS2-Q2L(3XFLAG) 
mutant recovered agonist responsiveness in a proteasome-dependent manner (Figure 2.6A and 
B). Moreover, recovery was faster and more extensive, as expected if RGS2-Q2L(3XFLAG) is 
proteolyzed faster than M1-RGS2(3XFLAG).  Conversely, cells expressing the slowly degrading 
RGS2-F6D(3XFLAG) mutant showed insignificant resensitization within 40 min after treating 
cells with CHX without or with MG-132 (Figure 2.6A and B). These results provide the first 
evidence indicating that proteasome-mediated degradation of RGS2 directly determines the rate 
and extent that cells recover agonist responsiveness or resensitize once RGS2 expression ceases. 
Taken together, our findings indicate that proteolytic degradation of RGS2 can serve at least two 
functions:  1) determine agonist efficacy by setting steady-state expression levels of RGS2 
protein; and 2) determine the rate that cells recover agonist efficacy as RGS2 expression ceases.   
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DISCUSSION  
Here we have shown in Gq-mediated GPCR signaling that agonist efficacy and recovery 
of agonist responsiveness (“resensitization”) can be regulated by proteolytic degradation of 
RGS2.  Besides establishing regulatory functions of RGS2 proteolysis in GPCR signaling, our 
findings reveal unexpected complexity of mechanisms that proteolytically degrade RGS2.   
In several cell types and organs, RGS2 mRNA expression is upregulated transiently in 
response to various extracellular stimuli, GPCR agonists or second messengers, potentially 
providing negative feedback or cross-regulation of signaling pathways controlled by RGS2 (34). 
Our findings suggest that, by affecting the level of RGS2 protein expressed, proteolytic 
degradation is capable of determining the magnitude of the inhibitory effect achieved by RGS2 
mRNA upregulation. Moreover, because we found that proteolysis of RGS2 determines how 
quickly cells recover agonist responsiveness after RGS2 expression stops, this mechanism also is 
capable of determining the rate that feedback or cross-regulation of cell signaling is relieved as 
RGS2 mRNA expression declines. Additional factors are likely to influence such functional 
outcomes because protein kinase C, cGMP-dependent protein kinase and cardiac glycosides can 
regulate RGS2 proteolysis, providing further control of feedback or cross-regulation of GPCR 
signaling by RGS2 (40–42).  
Our findings indicate that proteolytic degradation of RGS2 is considerably more complex 
than previously appreciated. Beyond prior understanding that RGS2 degradation via the Ac/N-
end rule pathway depends on N-terminal acetylation and the identity of the amino acid at 
position 2, we have found that RGS2 degradation requires two internal motifs: a hydrophobic 
region proximal to the N-terminus and an amphipathic α-helical region located more distally. 
Whether these two degradation signals are recognized physically or functionally by TEB4 
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(MARCH6) in the Ac/N-end rule pathway, or other proteins implicated in RGS2 degradation 
including CUL4B/DDB1/FBXO44 complexes remains unclear.  
TEB4/MARCH6 and its yeast homolog Doa10 require their conserved hydrophobic C-
terminal domains for substrate degradation (50). Whether these C-terminal domains function by 
binding directly to substrate proteins or accessory factors that promote substrate utilization 
remains unclear. In yeast, Doa10-mediated substrate degradation requires Hsp70 and Hsp40 
chaperones and co-chaperones, although how these accessory proteins function with Doa10 
remains to be established (51). Degradation signals in substrate proteins targeted in yeast by 
Doa10 are exposed hydrophobic faces of amphipathic α-helices (52), whereas those recognized 
in mammalian cells by TEB4/MARCH6 have yet to be characterized.  Although TEB4 can bind 
a GST fusion protein bearing the first 10 residues of RGS2, which includes the hydrophobic 
motif but excludes the amphipathic helix, it is unclear whether this physical interaction is 
required to degrade RGS2 or whether TEB4 targets RGS2 indirectly by interacting with 
chaperone/co-chaperone complexes.  
By comparison, degradation signals in substrates targeted by CUL4B/DDB1/FBXO44 
complexes have yet to be characterized in any detail.  
We attempted to address such questions by determining whether disrupting either the N-
terminal hydrophobic motif or the amphipathic helix of RGS2 is sufficient to abrogate 
interaction with transfected CUL4B or TEB4. Interaction occurred for degradation-resistant 
forms of RGS2 and CUL4B or TEB4 in co-immunoprecipitation and affinity purification 
experiments, respectively (Figure 2.7). Thus, further work will be required to determine how the 
N-terminal hydrophobic motif and amphipathic helix of RGS2 promote proteolytic degradation.  
Potential mechanisms could include events subsequent to ubiqutination, such as recognition or 
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unfolding of ubiquitinated RGS2 by the proteasome, as suggested by recent studies of other 
degradation-promoting signals (53). 
Mechanisms that regulate RGS2 degradation also remain to be understood in detail. 
Cardiac glycosides, protein kinase C or cGMP-dependent protein kinase (cGK) all regulate 
RGS2 degradation (40–42).  However, whether these mechanisms directly target RGS2 or the 
machinery that mediates RGS2 degradation is unclear. PKC can directly phosphorylate RGS2, 
but whether this is sufficient to inhibit RGS2 degradation has not been determined (54). 
Regulation of RGS2 degradation by cGK activity apparently occurs by more than one 
mechanism because inhibition of this protein kinase blunts RGS2 degradation whereas 
inactivation of the cGK phosphorylation sites in RGS2 promotes degradation.  
In conclusion, by showing in Gq-mediated GPCR signaling that proteolytic degradation 
of RGS2 is capable of regulating agonist efficacy and the rate that cells recover agonist 
responsiveness (“resensitization”) as RGS2 expression is terminated, our findings suggest that 
targeting proteolytic mechanisms might provide avenues to treat diseases such as hypertension 
and anxiety that have been linked to partial loss of RGS2 expression or function. Various steps in 
the processes that mediate or regulate proteolytic degradation of RGS2 therefore may provide a 
multiplicity of targets to pursue for therapeutic benefit.  
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MATERIALS AND METHODS 
Plasmids – pcDNA3.1 vector (ThermoFisher Scientific) was used to drive expression of 
all RGS2 constructs used in this study.  All constructs were prepared by PCR cloning using Kapa 
Taq polymerase (Kapa Biosystems, cat.KK1006).  All mutations were generated with site 
directed mutagenesis, and all deletion mutants were made with PCR-mediated ligation.  M1-
RGS2(3X-FLAG) was used as a template for all RGS2 expression constructs, and it was 
generated by mutating all internal translation start sites (ATG) to leucine (CTG) on the WT-
RGS2(3X-FLAG) expression construct.  GFP fusion proteins were generated by cloning PCR 
amplified fragments of RGS2 into a pcDNA3.1-N-MCS-GFP expression construct.  pcDNA3.1-
N-MCS-GFP was generated by cloning GFP from eGFP-N (Clontech) into pcDNA3.1.  Twitch-
2B pcDNA3, a FRET based calcium reporter, was a gift from Oliver Griesbeck (Addgene 
plasmid # 49531) (49),  MYC-CUL4B was a gift from Helen Piwnica-Worms (The University of 
Texas, MD Anderson Cancer Center), TEB4-HIS-MYC was a gift from Mark Hochstrasser 
(Yale University School of Medicine).  
Antibodies and reagents – Mouse anti-FLAG M2 (Sigma, cat.F1804, various lots), 
Mouse anti-Actin C4 (Milipore, cat.MAB1501, lot NG1812617), Rabbit anti-GFP (Abcam, 
cat.AB290, various lots), Odyssey infrared secondary antibodies: Goat anti-Mouse 
IRDye800CW (Licor, cat. 926-32210, lot C30702-01), Goat anti-Rabbit IRDye680RD (Licor, 
cat.926-68071, lot C3081502), HRP conjugated Mouse-anti-FLAG M2 (Sigma, cat. A-8592), 
HRP conjugated mouse anti-MYC (9e10) (ThermoFisher Scientific  cat.MA1-980-HRP), mouse 
anti-FLAG M2 resin (Sigma, cat.A2220), Ni-NTA agarose (Qiagen, cat.1018244), 
cycloheximide (Sigma, cat.C7698), MG-132 (Calbiochem, cat.47479D), carbachol (Sigma, 
cat.C4382) 
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 Cell culture and transfections – HEK293 and A7r5 cells (ATCC, CRL-1444) were grown 
in DMEM/F12 (ThermoFisher Scientific, cat.11330-032) with 10% FBS (Atlanta Biologicals, 
cat.S11150) and penicillin/streptomycin (ThermoFisher Scientific, cat.15140122), at 37C and 
5% CO2 in a humidified incubator.  All transfections were performed with TransIT-LT1 (Mirus 
Bio, cat.MIR2305) according to the manufacturer’s protocol.  HEK293 cells were transfected in 
suspension.  
Cycloheximide chase assay – All cycloheximide chase assays were performed in 
HEK293 cells.  For assays in Figure 2.4, cells were transfected with the indicated RGS2-GFP 
fusion.   Expression levels of RGS2-GFP were normalized to endogenous actin (see 
quantification method).  For all other cycloheximide chase assays, cells were co-transfected with 
GFP and the indicated RGS2 variant, and expression levels of RGS2-FLAG were normalized to 
GFP (see quantification method).  20-24 hours after transfection, cells were treated with 
cycloheximide (30ug/ml) for the indicated times and lysed with radioimmunoprecipitation 
(RIPA) assay buffer (150 mM sodium chloride, 1% Triton-X100, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) with 1X Complete Protease Inhibitor (Roche, 
cat.11697498001), and then mixed with Laemmli buffer (25% glycerol, 2% sodium dodecyl 
sulfate, 0.01% bromophenol blue, 62.5 mM Tris pH 6.8).  
Samples were resolved with 15% SDS-PAGE, and transferred to Immobilon(P)-FL 
fluorescence optimized PVDF membrane (Milipore, cat.IPFL00010). Membranes were blocked 
with 5% w/v milk in TBST (25 mM Tris pH 7.2, NaCl 150 mM, 2.7 mM KCl, 0.1% v/v Tween 
20) and incubated with the indicated primary antibody.  Membranes were washed with TBST at 
least three times and incubated with the appropriate secondary antibody.  Following incubation, 
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membranes were washed at least three times with TBST and signals were detected using 
Odyssey Infrared Imaging System (Licor).  
Quantification and analysis of cycloheximide chase assay – Signal intensity of the 
western blot bands were quantified with imaging software Odyssey v2.1 (Licor).  All bands were 
within the linear range of detection.  Where indicated, signal intensity of FLAG was normalized 
to either actin or GFP.  Data are expressed as a percentage of initial (t=0) normalized protein 
levels.   All results shown are an average of at least 3 experiments.   
Qualitative analysis of RGS2 steady state expression in A7r5 cells – A7r5 cells were co-
transfected with GFP and RGS2 variants for 36-48 hours.  Samples were prepared with the same 
western blot protocol as cycloheximide chase assays.  RGS2-FLAG, however, was detected 
using the HRP conjugated anti-FLAG M2 primary antibody, ECL solution (GE Healthcare, cat. 
RPN2106), and ChemiDoc Imaging Systen (BioRad).  Actin and GFP were detected with the 
Odyssey Infrared Imaging system as described above.   
Agonist evoked calcium flux assay– HEK293 cells were co-transfected in suspension with 
plasmid for calcium reporter Twitch-2b (49) and plasmid for the indicated variant of RGS2  and 
plated on black wall clear bottom 96 well-plate (Costar, cat.3603) that was coated with poly-D-
Lysine (Sigma, cat.P0899).   20-24 hours after transfection, cells were prepared for the agonist 
evoked calcium flux assay or processed for western blot analysis and imaged with the Odyssey 
Infrared Imaging System as described above. For the calcium flux, cell growth media was 
replaced with prewarmed (37C) imaging buffer (125nM NaCl, 5mM KCl, 1.5mM MgCl2, 
1.5mMCaCl2, 10mM D-glucose, 20mM HEPES, pH 7.4) (55) and assayed immediately in a 
Synergy H4 Hybrid Reader (Biotek) equipped with an agonist injection pump.  All assays were 
performed at 37C.  For assays involving drug pre-incubation, cells were incubated with 
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cycloheximide (30ug/ml) and DMSO (vehicle control) or cycloheximide and MG132 (50uM) in 
imaging buffer for the indicated times in 37C prior to agonist stimulation.   
Detection and quantitation method of calcium signaling assay – FRET donor was 
continuously excited with a bandpass filter 420/20, and donor and acceptor emissions were 
detected by switching filters every 49 miliseconds using 480/20 and 540/20 filters, respectively.  
A dichroic mirror with a 455nm cut off was used to separate the excitation and emission light 
paths. Changes in [Ca
2+
]i were expressed as: 
∆𝑅
𝑅𝑜
= 
𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 −𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜
 
where FRET ratio = (540nm
emission
/480nm
emission
) at any time-point, and the baseline FRET ratio 
= average of (540nm
emission
/480nm
emission
) prior to agonist stimulation.  One experiment is the 
average of triplicates. 
Statistics- Statistical significance of cycloheximide chase assays and agonist evoked 
calcium signaling assays were determined by two way ANOVA followed by Bonferroni’s post-
hoc test. 
Co-immunoprecipitation – HEK293 cells co-transfected with MYC-Cullin4B and 
indicated variants of M1-RGS2(3XFLAG) were incubated with MG132 (10uM) for four hours, 
then lysed and harvested in RIPA buffer.  Lysates were co-immunoprecipated with FLAG-M2 
resin and eluted by boiling in Laemmli buffer.  Lysates and eluates were resolved with 12% 
SDS-PAGE, transferred to PVDF, and processed for immunoblotting as described above.  FLAG 
and MYC tagged proteins were detected with HRP-conjugated anti-FLAG (M2) and HRP-
conjugated anti-MYC(9e10) primary antibodies, respectively. 
In-cell cross linking and Ni-NTA pull down – HEK293 cells co-transfected with TEB4-
HIS-MYC and indicated variants of M1-RGS2(3XFLAG) were incubated with MG132 (10uM), 
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then crosslinked with 1mM DSP((dithiobis(succinimidyl propionate))) (ThermoScientific, cat. 
22586)  for 2 hours on ice.  Crosslinking reaction was quenched with Tris-HCl pH 7.5 for 15min 
at room temperature, and cells were carefully harvested.  Cells were spun down, quenched 
crosslinking buffer removed, and lysed in triton buffer.  Lysate was centrifuged and supernatant 
was applied to Ni-NTA for 1.5hrs at 4C.  Ni-NTA resin was extensively washed with 100x resin 
volume and eluted with 200mM imidazole pH 8.0.  Crosslinking was reversed with 50mM DTT 
at 37C for 30 minutes and samples were resolved with 12% SDS-PAGE, transferred to PVDF, 
and processed for immunoblotting as described above.  FLAG and MYC tagged proteins were 
detected with HRP-conjugated anti-FLAG (M2) and HRP-conjugated anti-MYC(9e10) primary 
antibodies, respectively.   
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FIGURE 2.1.  Generation of expression construct for full length RGS2   
(A) A schematic of RGS2’s domain architecture and expression constructs used in this study.  
The RGS domain is flanked by an N-terminal region that contains multiple start codons, as 
indicated by vertical bars and arrows.  The start codons are numbered by their amino acid 
positions.  All expression constructs are tagged on the C-terminus with the 3X-FLAG epitope, as 
indicated by “3X-F”.  (B) The WT-RGS2(3X-FLAG) construct contains all start codons and 
expresses all translation products.  The alternative translation products are named according to 
the amino acid position of their respective ATG start sites.  Full length RGS2, which is translated 
from methionine at position 1, is termed M1, and so on.  The expression constructs for the 
alternative translation products produce only single products and migrate to their expected 
molecular weight.  (C) Cycloheximide chase assays were performed to assess stability of the 
alternative translation products and quantified in (D) (See Experimental Procedures).  The error 
bars are SEM, *,p<0.05;  **,p<0.01; vs M1.  
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FIGURE 2.2.  Characterization of novel hydrophobic degradation signal in the N-terminus and 
generation of stable mutants 
(A) Schematic of mutants tested in the deletion analysis.  The mutants were named according the 
deleted residues, and the deleted regions are indicated by connecting dotted lines.  (B) 
Cycloheximide chase assays were performed to assess stability of deletion mutants and 
quantified in (C).  Error bars are SEM, *,p<0.05 vs M1.  (D) Amino acid sequence from residue 
1-11 for the expression constructs M1-RGS2(3X-FLAG) and mutants. The mutants were named 
according to their respective amino acid substitution, and the mutated residues are highlighted.  
(E) Cycloheximide chase assays were performed to assess the effects of the point mutations on 
stability and quantified in (F).  Error bars are SEM, *,p<0.01; **,p<0.05 vs M1. (G) Amino acid 
sequence from residue 1-11 for the mutants with scrambled residues.  Mutants were named Scr1 
and Scr2.  (H) Cycloheximide chase assays were performed to assess stability of scrambled 
mutants and quantified in (I).   
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FIGURE 2.3.  Generation and characterization of Q2L-RGS2(3X-FLAG) expression construct 
(A) Amino acid sequence of residues 1-11 for the various expression constructs, which were 
named according to their amino acid substitution, deleted regions, or both.  (B) Cycloheximide 
chase assays were performed to assess stability of expression constructs containing the Q2L 
mutation and quantified in (C).  Error bars are SEM. Expression levels of Q2L-RGS2(3X-
FLAG) were below the linear range of detection past the 30 minute time point and thus were not 
quantified.  (D) Relative steady state expression levels of RGS2 variants in A7r5 cells.  GFP was 
co-transfected with the respective RGS2 variant and served as transfection control, and 
endogenous actin served as loading control.  Results are representative of 3 experiments. 
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FIGURE 2.4.  Generation and characterization of GFP fusion proteins and amphipathic helix 
mutants 
(A) Schematic of RGS2-GFP fusion proteins.  M1-GFP is a fusion of full length M1-RGS2 to 
GFP.  The other GFP fusion proteins were named according to the portion of the RGS2 N-
terminal domain fused to GFP.  The numbers in the parentheses indicate the exact residues 
included or excluded.  (B) GFP fusion proteins were transfected in HEK293 cells and their 
expression was confirmed by western blot.  Proteolytic products are indicated by *.  (C) 
Cycloheximide chase assays were performed to assess stability of GFP fusion proteins and 
quantified in (D).  Error bars are SEM, *,p<0.05; **,p<0.01 vs (1-80)-GFP and #,p<0.05 vs M1-
GFP.  (E) A helical wheel representation of the amphipathic helix.  The hydrophobic residues are 
colored in grey and the mutated residues are highlighted by dashed lines. (F) Amino acid 
sequence of residues 40-53 for various expression constructs, which were named according to 
their amino acid substitution. (G) Cycloheximide chase assays were performed to assess stability 
of amphipathic helix mutants and quantified in (H). Error bars are SEM, *,p<0.001; **,p<0.01 vs 
M1. 
 
 
 
 
 
 
 
 
  
65 
  
  
 
 
 
  
66 
  
  
 
FIGURE 2.5.  RGS2 stability determines steady state expression levels and agonist efficacy 
(A) HEK293 cells were transfected with increasing amounts of plasmid (13, 25, 50, 75, or 100 
ng/well) for M1-, Q2L-, or F6D-RGS2(3X-FLAG).  Expression of RGS2 variants were 
confirmed by western blot analysis.  Expression plasmid for Twitch-2B was co-transfected with 
a fixed amount (100ng/well) and detected by GFP primary antibody (see methods).  Twitch-2B 
expression also served as a transfection control. The western blots are representative of at least 
three independent transfections.  (B) The western blot bands for M1 or F6D were normalized to 
Twitch-2B.  The RGS2/Twitch-2B ratio was normalized to the RGS2/Twitch-2B ratio obtained 
from the maximum observed expression (100ng/well), and plotted against the amount of plasmid 
that was transfected. (C) Cells were stimulated with a dose of Carbachol (CCh) that elicits 
maximum calcium flux (indicated by the arrows), and the changes in [Ca
2+
]i were reported as 
ΔR/Ro (See Experimental Procedures).  In cells with no RGS2 plasmid transfected (0 ng 
plasmid, magenta traces), CCh elicited peak [Ca
2+
]i values of ~2.5-3 ΔR/Ro.  Peak [Ca
2+
]i values 
diminished in proportion to higher RGS2 levels.  The traces are an average of three independent 
experiments performed in triplicate, and a trace from one replicate represents the collective 
change in [Ca
2+
]i from 40,000-60,000 cells (one well).  (D) RGS2 function is represented as 
agonist efficacy, as quantified by normalizing peak [Ca
2+
]i values to peak [Ca
2+
]i values observed 
in the absence of RGS2 [(max ΔR/Ro of Xng RGS2)/ (max ΔR/Ro of 0ng RGS2)] x 100.   The 
bar graphs represent an average of three independent experiments performed in triplicate.  The 
error bars are SEM. * p<0.05, **p<0.001, vs M1.  
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FIGURE 2.6.  Proteasome mediated degradation of RGS2 dynamically regulates Gq evoked 
calcium flux 
 (A) HEK293 cells transfected with 100 ng/well of pcDNA3.1 (no RGS2) or the indicated RGS2 
variant were incubated with cycloheximide alone (top row) or with cycloheximide and MG132 
(bottom row) for the indicated time intervals (represented in color) prior to stimulation with CCh 
(indicated by arrows).  Changes in [Ca
2+
]i were reported as ΔR/Ro (See Experimental 
Procedures).   The traces are color coded to illustrate the time of pre-incubation with drug(s).  
Each trace is an average of three independent experiments performed in triplicate and a trace 
from one replicate represents the collective change in [Ca
2+
]i from 40,000-60,000 cells (one 
well).    (B) Peak [Ca
2+
]i is plotted against time to illustrate changes in agonist efficacy over time.  
The left and right panels represent peak [Ca
2+
]i from cells incubated with cycloheximide only or 
CHX+MG132. The bar graphs represent an average of three independent experiments performed 
in triplicate.  The error bars are SEM. 
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FIGURE 2.7.  Deletion of hydrophobic motifs do not abrogate interactions with CUL4B and 
TEB4 
(A) HEK293 cells co-expressing cullin4B-MYC and the indicated RGS2-3XFLAG variant were 
treated with MG132 for 4hrs (10uM) prior to lysis and immunoprecipitation with anti-FLAG 
resin.  Input and immunoprecipitations were immunoblotted with HRP conjugated anti-FLAG or 
anti-MYC. (B) HEK293 cells co-expressing TEB4-His-MYC and the indicated RGS2-3XFLAG 
variant were incubated with MG132 for 4hs (10uM) prior to crosslinking with membrane 
permeable agent DSP.  Cells were collected, lysed, and incubated with Ni-NTA resin to bind 
TEB4-His-MYC.  After elution, crosslinks were reversed prior to SDS-PAGE.   Membranes 
were immunoblotted with HRP conjugated anti-FLAG and anti-MYC.  
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Chapter 3 
 
Investigation of the GDI Mechanism for YM-254890 
and FR900359 
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ABSTRACT 
Heterotrimeric G proteins propagate signal transduction cascades responsible for many 
physiological and disease processes, and therefore many have sought to develop G protein 
inhibitors for research and clinical use.  YM-254890(YM) and FR900359(FR) are selective and 
cell permeable small molecule inhibitors for G proteins, which make them powerful research 
tools and promising leads for therapeutic agents.  YM and FR’s selectivity for G protein subunits 
have been characterized, and they have been shown to inhibit G protein activity by preventing 
GDP release, which functionally classifies them as guanine dissociation inhibitors (GDI).   It is 
inferred from several observations that YM/FR functions as a GDI through an allosteric 
mechanism, but the molecular details of this allosteric mechanism is still lacking.  The work 
described here is the first step towards addressing the hypothesis that YM/FR allosterically 
inhibits GDP release by stabilizing the network of intramolecular interactions that stabilize the 
GDP bound conformation of Gα subunits. The interaction network is part of the universal G 
protein activation mechanism, which becomes destabilized to effect GDP release and G protein 
activation.   
As a first step towards addressing this allosteric model of inhibition, it was determined 
whether YM/FR inhibits the universal G protein activation mechanism. The YM/FR binding 
pocket on Gq is conserved but in a divergent form in all Gα subunits.  Furthermore, this binding 
pocket contains key structures that participate in the universal G protein activation mechanism.  
Therefore, it was hypothesized that introducing YM binding sites to an otherwise YM-insensitive 
G protein should be sufficient to confer YM sensitivity.  Results show that a Gαi1 mutant 
(Gαi1(FR)) that contains eight FR binding residues exhibits FR sensitivity, which indicates that 
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specificity of YM/FR is due solely to the unique features of the binding site of Gq/11, and also 
provides supporting evidence that FR is inhibiting the universal activation mechanism.  This is 
followed by a discussion of future experiments that will determine whether FR sensitivity of 
Gαi1(FR)) is mediated through an allosteric mechanism.  
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INTRODUCTION 
G protein coupled receptors (GPCR) comprise the largest family of cell surface receptors 
and are the targets of ~30% of drugs on the market (1, 2).  GPCR targeted therapies are used to 
treat many diseases including pain, inflammation, certain cancers, and a variety of neurologic 
and cardiovascular diseases (3, 4).  However, this strategy may not be effective for diseases 
driven by multiple GPCRs that redundantly activate common G protein signaling pathways or by 
mutations that cause constitutive activation of Gα subunits independent of GPCRs.  It is also 
common that a particular GPCR can activate more than one type of Gα subunit as well as non-G 
protein signaling pathways (e.g. β-arrestin), and therefore blocking one GPCR could lead to 
silencing signaling pathways not related to diseases processes and can cause adverse side effects 
(5).  To circumvent the drawbacks of GPCR targeted therapies, targeting G proteins might 
provide a more precise way to silence signal transduction pathways that drive disease 
progression (6).  
G protein inhibitors have been developed and studied over the last several decades, but 
all have lacked the selectivity and pharmacokinetic properties desired for clinical use (6–8).  
However, recent breakthroughs have made evident that selective inhibition of G proteins is 
possible and has motivated several groups, including ours, to understand the molecular and 
structural mechanisms by which these compounds inhibit G protein activity (9–12).      
In 2003, Yamanouchi Pharmaceutical isolated a compound from Chromobacterium sp. 
QS3666 that was demonstrated to attenuate physiological processes driven by Gq such as platelet 
aggregation, thrombosis and blood pressure (9, 13–15).  Structural analysis revealed the 
compound is a cyclic depsipeptide and was named YM-254890(YM) (Figure 3.1).  Biochemical 
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analysis indicated that YM works as a guanine dissociation inhibitor (GDI) and is selective for 
Gq but not for Gs, Gi/o, or G13  (9, 12). 
Recently, a compound of similar structure, selectivity, and potency towards Gq called 
FR900359(FR) was characterized (Figure 3.1) (10).  The compound was originally isolated in 
1988 from Ardisia crenata (16), a plant native to Southeast Asia, but its properties as a selective 
inhibitor for Gq was not appreciated until more recently. Biochemical analysis demonstrated that 
FR functions as a GDI and selectively inhibits Gq, G11, and G14, but not G16, Gi/o, Gs, or 
G12/13 (10).  
YM and FR are the only small molecule inhibitors for G proteins that are both selective 
and cell permeable (10, 12, 14, 17).  Although YM and FR have been functionally classified as 
GDIs (10, 17), the exact molecular mechanism of action of YM/FR is still unknown.  
A YM-Gq co-crystal structure shows that YM binds to a hydrophobic pocket on Gq that 
is conserved but divergent in other classes of Gα subunits (Figure 3.2 and Figure 3.4) (17).  
Mutational analysis performed in parallel showed selectivity is due to the unique residues in the 
binding pocket of the Gq/11 family (with exception to G15 and G16) (17).  From this structure, it 
was inferred that YM allosterically inhibits GDP release by stabilizing Switch I and Linker 1, 
which are flexible hinge regions associated with inter-domain opening and GDP release (18).   
Further supporting the allosteric mode of inhibition is a molecular dynamics simulation 
of FR bound to Gq that found FR stabilized Switch II and the α5 helix, which are regions distal 
to the FR binding pocket associated with conformational change during G protein activation 
(10).  FR stabilizes structures far from the FR binding site, suggesting an allosteric mechanism of 
inhibition.  
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One mechanism that has not been explored is whether YM/FR inhibits GDP release by 
allosterically inhibiting the universal G protein activation mechanism. The YM/FR binding 
pocket contains structures that participate in the universal G protein activation mechanism – 
structures and intramolecular interactions that become destabilized to effect inter-domain 
opening and GDP release (described in Figure 3.3) (19).  YM/FR directly contacts such 
structures involved in the network of interactions that stabilize the GDP bound conformation of 
Gα subunits (α1 helix, linker 1, and αA helix, Figure 3.2 and 3.3) (10, 17), suggesting that 
YM/FR may allosterically inhibit GDP release by stabilizing this network of interactions. Based 
on these observations, it was hypothesized that YM/FR allosterically inhibits GDP release by 
stabilizing structures that become disordered by the universal G protein activation mechanism. 
Here, the results of preliminary experiments that begin to address this hypothesis are 
presented.  As a first step towards testing this hypothesis, it was determined whether FR/YM can 
inhibit the universal G protein activation mechanism.  
As described above, the YM/FR binding pocket of Gq is conserved but in a diverged 
form in other Gα subunits (17).  Although this binding pocket in other Gα subunits do not have 
the YM/FR specific residues, they still contain the structures that participate in the universal G 
protein activation mechanism (17, 19).  Therefore, it was hypothesized that if YM/FR works by 
inhibiting the universal G protein activation mechanism, then introduction of YM binding sites to 
an otherwise YM-insensitive G protein should be sufficient to confer YM sensitivity.  This was 
tested by determining whether a Gαi1 mutant with FR binding sites will exhibit sensitivity to FR.  
Results show that a recombinant Gαi1 protein that contains FR binding sites (Gαi1(FR)) gains 
sensitivity to FR.  To determine whether inhibition occurs through an allosteric mechanism, 
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additional experiments are required and are discussed below.  Furthermore, preliminary data for 
a cell-based assay that will help streamline mutational analysis of Gαi1(FR) variants are presented.  
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RESULTS 
Gαi1 was chosen for this study because recombinant Gαi1 exhibits spontaneous 
nucleotide exchange, and therefore its “activity” can be measured using the fluorescent probe 
BODIPY-GTPγS (20).  
Cloning FR sensitive mutants – A Gαi1 mutant was generated by introducing eight amino 
acid substitutions in the hydrophobic pocket of Gαi1 analogous to the YM binding pocket on Gq, 
and the mutant was called Gαi1(FR) (Figure 3.4).  The mutations introduced YM interaction 
residues unique to Gq . 
Testing FR sensitivity – To determine whether Gαi1(FR) exhibits sensitivity to FR, in vitro 
spontaneous nucleotide exchange assays were performed on purified recombinant Gα subunits.  
It was first determined whether the mutations affected folding or stability of Gαi1(FR).  The yield 
of recombinant Gαi1(FR) was comparable to Gαi1, and a Coomassie stain showed little 
proteolytic product, which indicated that the mutation has negligible or insignificant effects on 
folding or stability of the protein (data not shown). 
Spontaneous nucleotide exchange of recombinant Gα  subunits was assessed by the 
fluorescence increase that is observed upon Gα binding to BODIPY-conjugated GTPγS (20).  In 
a control experiment, a representative trace of time dependent nucleotide exchange for Gαi1 is 
shown (Figure 3.5A and B).  As expected, the addition of GoLoco peptide, a GDI for Gαi1, 
reduces maximum nucleotide exchange achieved in the 40 minute time course in a dose 
dependent manner.  
Maximum spontaneous nucleotide exchange for Gαi1(FR) was inhibited by FR in a dose 
dependent manner (Figure 3.5D).  Gαi1 also exhibited sensitivity to FR but required ~10 times 
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more FR to achieve the same amount of inhibition as Gαi1(FR) (Figure 3.5C).  To determine 
whether Gαi1(FR) and Gq exhibit FR sensitivity through similar contact residues, a mutant version 
of Gαi1(FR) that is equivalent to a Gq mutant that has reduced sensitivity to FR was made (17).  A 
R54K amino acid substitution (equivalent to R60K on Gq) was made on Gαi1(FR)  to generate 
R54K-Gαi1(FR)  (Figure 3.4)  Spontaneous nucleotide exchange for R54K-Gαi1(FR) was inhibited 
in a FR dose dependent manner similar to Gαi1.   
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DISCUSSION 
The results demonstrated that introducing FR binding sites to the hydrophobic binding 
pocket of Gαi1 is sufficient to inhibit spontaneous nucleotide exchange.   This is supporting 
evidence for the model that FR inhibits the universal activation mechanism for G proteins.  
However, additional experiments are necessary to determine whether the observed FR sensitivity 
of Gαi1(FR) is mediated by an allosteric mechanism.   
A follow-up study that involves the R54K-Gαi1(FR) mutant would help determine whether 
FR is inhibiting nucleotide exchange by an allosteric mechanism. The R54 residue in Gαi1(FR), 
which is analogous to R60 in Gq, is a residue that contacts YM/FR and also is a key residue on 
the α1 helix that stabilizes the GDP bound conformation of Gα (Figure 3.3) (19).  Therefore, the 
loss of FR sensitivity for R54K-Gαi1(FR) could be due to the loss of allosteric communication 
between FR and residue R54.  This hypothesis can be tested by determining whether R54K-
Gαi1(FR) and FR still exhibit binding despite the reduction in FR sensitivity.  The binding status 
of FR and G proteins can be assessed using techniques like isothermal calorimetry or surface 
plasmon resonance (21, 22). If R54K-Gαi1(FR) and FR exhibit binding,  this would provide 
evidence that FR inhibits the universal activation mechanism through an allosteric mechanism.  
Furthermore, this would implicate the R54 residue as a conduit that transmits allosteric 
stabilization by FR to the universal activation mechanism.  If R54K-Gαi1(FR) does not bind FR, it 
would not exclude the allosteric inhibition model, but it would indicate R54K is necessary for 
interaction with FR. 
If R54K-Gαi1(FR) does not yield a conclusive result regarding the allosteric mechanism, 
additional Gαi1(FR) mutants  can be tested to address the same question.  For example, there are 
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two additional residues with properties equivalent to R54 in that they interact with FR and the 
network of intramolecular contacts that stabilize the GDP bound conformation of G alpha 
subunits.  These residues are Y61 and F69 on Gαi1(FR), which are analogous to residues Y67 
(Linker 1) and F75 (αA helix) on Gq (highlighted in red on Figure 3.3) (17, 19).  If amino acid 
substitutions at Y61 and F69 that retain FR binding but exhibit poor sensitivity to FR can be 
identified, this would provide evidence that FR inhibits G protein activity by an allosteric 
mechanism.   
The allosteric inhibition model can be tested further by performing mutational analysis on 
residues that participate in the universal activation mechanism but do not contact FR.  Such 
residues include those that stabilize interactions with α5 (T48 on α1 helix) or GDP (Q52 on α1 
helix), or residues further from the FR binding pocket that make extensive stabilizing 
interactions with GDP, α5 helix, and the α-helical domain (K270 on α5 helix) (highlighted in 
yellow on Figure 3.3) (17, 19).  By introducing mutations that disrupt the stable intramolecular 
interactions provided by these residues, it can be predicted that FR cannot inhibit these mutants 
because the FR binding residues in the binding pocket will not be coordinated for FR.    
Therefore, these mutations will neither bind nor exhibit sensitivity to FR.  Going forward, these 
types of mutational analyses should help determine whether FR is inhibiting GDP release by 
allosteric inhibition of the universal activation mechanism.   
In order to make the mutational analysis rapid and streamlined, the activity assay for 
Gαi1(FR) was adapted for a cell-based assay.  This assay measures G protein activity by 
monitoring cytoplasmic changes in cyclic-AMP (cAMP) levels using a genetically encoded 
fluorescent cAMP sensor H187S(23).  Gαi1 activity in particular will be measured by monitoring 
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Gαi-agonist mediated inhibition of adenylyl cyclase activity.  To ensure that only the activity of 
the Gαi1 mutant of interest is measured, cells are treated with pertussis toxin (PTX) to silence all 
endogenous Gαi1.  Furthermore, all Gαi1 mutants of interest will contain the point mutation 
(C351G) to render them PTX insensitive (24). 
Figure 3.6 demonstrates this signaling assay allows for exclusive activity measurement of 
exogenous Gαi1.  Gαi activity is measured by first eliciting maximum cAMP production with 
forskolin and then stimulating with DAMGO, a selective agonist for μ opiod receptors.  
Reduction in cAMP levels is observed in cells expressing WT Gαi1, but this reduction is 
attenuated in PTX treatment.  On the other hand, DAMGO mediated reduction in cAMP levels 
were not affected for cells expressing PTX insensitive mutants, EE(C351G)-Gαi1 and 
EE(C351G)-Gαi1(FR).  Follow up experiments will determine whether FR sensitivity of 
EE(C351G)-Gαi1(FR) is recapitulated in live cells.   
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MATERIALS AND METHODS 
Plasmids – pcDNA3-Twitch-2B was a gift from Dr. Oliver Griesbeck (Addgene plasmid 
#49531). pcDNA3-Epac-S
H187 
cAMP FRET sensor was generously provided by Dr. Kees Jalink, 
Netherlands Cancer Institute, Amsterdam (23), pcDNA3-HA-μOR was cloned by PCR 
amplification μ opiod receptor with an N-terminal HA epitope tag, pcDNA3-EE-Gαi1 was 
purchased from cDNA.org (cat. GNAI10EI00), PTX insensitive mutant pcDNA3-EE-Gαi1 
C351G was generated by site directed mutagenesis, recombinant Gα subunits, Gαi1, Gαi1(FR), and 
Gαi1(FR) R54K,  were expressed from pet14B (N-terminal 6X-HIS epitope tag): pet14B-Gαi1(FR) 
was generated by cloning a custom G-block (IDT) with the In-Fusion Cloning Kit (Clontech 
cat.639689).  pet14B-Gαi1(FR) R54K was generated by site directed mutagenesis.   
Reagents and antibodies – BODIPY® FL GTP-γ-S, Thioester (ThermoFisher 
cat.G22183), Carbachol (Sigma cat.C4382), DAMGO (Sigma cat.E7384), GoLoco peptide 
(Genscript, custom synthesis), pertussis toxin (Calbiochem cat. 516561, lot D00159812), 
Geneticin®/G418 (ThermoFisher cat. 10131035), mouse anti-HA.11 (Covance cat.MMS-101R), 
mouse anti-Glu-Glu (Covance cat.MMS-115P), mouse anti-actin C4 (Millipore cat.MAB1501), 
HRP-conjugated goat anti-mouse IgG (Thermo Scientific cat.31430) 
Cell culture and transfections – HEK293 cells were cultured and transfected as described 
in Materials and Methods section of Chapter 2.  The HA-μOR-HEK293 stable cell line was 
generated by transient transfection of HEK293 cells with pcDNA3-HA-μOR followed by G418 
selection (500ug/ml).  HA-μOR-HEK293 cells were cultured under the same conditions as 
HEK293 with the addition of G418 (100ug/ml) in the growth media.    
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cAMP reporter assay (Epac-S
H187
) – HEK293 cells were co-transfected with Epac-SH187 
cAMP FRET sensor and corresponding pcDNA3-EE-Gαi1 variant in suspension and plated on a 
black wall clear bottom 96 well-plate (Costar, cat.3603) coated with poly-D-Lysine (Sigma, 
cat.P0899).  After 6-10 hrs, transfection media was replaced with serum free media with or 
without pertussis toxin (100 ng/ml).  After 20-36 hrs, serum free media was replaced with 
prewarmed (37C) imaging buffer (125nM NaCl, 5mM KCl, 1.5mM MgCl2, 1.5mMCaCl2, 
10mM D-glucose, 20mM HEPES, pH 7.4) and assayed immediately in a Synergy H4 Hybrid 
Reader (Biotek) equipped with injection pumps. 
Detection and quantitation of cAMP levels – FRET donor was continuously excited with 
a bandpass filter 420/20, and donor and acceptor emissions were detected by switching filters 
every 10 seconds using 480/20 and 540/20 filters, respectively.  A dichroic mirror with a 455nm 
cut off was used to separate the excitation and emission light paths. Changes in cAMP levels 
were expressed as: 
∆𝑅
𝑅𝑜
= 
𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 −𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜
 
where FRET ratio = (480nm
emission
/540nm
emission
) at any time-point, and the baseline FRET ratio 
= average of (480nm
emission
/540nm
emission
) prior to agonist stimulation.  One experiment is the 
average of triplicates. 
 
Expression and purification of recombinant proteins – Recombinant Gα subunits were 
expressed and purified from E. coli using established methods (25).   
Spontaneous nucleotide exchange assay – In a black wall clear bottom 96 well-plate 
(Costar), recombinant Gα proteins (1uM) were pre-incubated in reaction buffer (50mM Tris-HCl 
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pH 8.0, 1mM EDTA, 10mM MgCl2) with DMSO (vehicle) or FR-900359 at the indicated 
concentration for 20 minutes at room temperature prior to measuring spontaneous nucleotide 
exchange. BODIPY-GTPγS was added (final concentration 25nM) at time=0, and changes in 
fluorescence was monitored in a Synergy H4 Hybrid Reader (Biotek) at 30
o
C.  The 
monochrometer was used to excite at 528/9 nm and detect emissions from 528/9 nm in 10 second 
intervals for 2000 seconds.    
Normalization and quantification of fluorescence units – The traces are averages of 3 
independent experiments.  Spontaneous nucleotide exchange is expressed as normalized 
fluorescence ΔF/Fo, where ΔF= F-Fo, F=fluorescence from Gα- BODIPY-GTPγS, and 
Fo=background fluorescence in the absence of Gα protein.  Spontaneous nucleotide exchange is 
quantified as the percentage of the maximum amplitude of ΔF/Fo observed in the absence of FR. 
The data are averages of 3 independent experiments, and error bars are standard error of the 
mean.   
SDS-PAGE and western blot analysis – Cells were lysed in radioimmunoprecipitation 
assay buffer (150 mM sodium chloride, 1% Triton-X100, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulfate, 50 mM Tris, pH 8.0) with 1X Complete Protease Inhibitor (Roche, 
cat.11697498001), and then mixed with Laemmli buffer (25% glycerol, 2% sodium dodecyl 
sulfate, 0.01% bromophenol blue, 62.5mM Tris pH).  Samples were resolved with 15% SDS-
PAGE, and transferred to Immobilon(P) PVDF membrane (Milipore, cat.IPVH00010). 
Membranes were blocked with 5% w/v milk in TBST (25 mM Tris pH 7.2, NaCl 150 mM, 2.7 
mM KCl, 0.1% v/vTween 20) and incubated with the indicated primary antibody.  Membranes 
were washed with TBST at least three times and incubated with the appropriate secondary 
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antibody.  Following incubation, membranes were washed at least three times with TBST and 
signals were detected using ChemiDoc Imaging System (Bio-Rad). 
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FIGURES 
 
 
FIGURE 3.1.  Structures of YM-254890 and FR900359 (adapted from (10)) 
YM-254890 and FR900359 are cyclic depsipeptides that are nearly identical in structure.  The 
differences in structure are highlighted in yellow and blue. 
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FIGURE 3.2.  Co-crystal structure of YM-254890 and chimeric Gi/q (taken from (17)) 
The two domains of the Gαq are color coded: GTPase domain is in yellow, and the helical 
domain is in green.  GDP is colored purple, and YM is colored blue.  YM binds in a pocket 
formed by the flexible linkers, Switch 1 and Linker 1 (colored red and labeled “hinge”), that 
connect the two GTPase and Helical domains.  The orientation of the YM binding pocket relative 
to the guanine nucleotide binding site is especially notable from these two angles.  YM does not 
make physical contact with the GDP binding site.  On the right figure, a key FR interaction 
residue on the α1-helix is highlighted as “Arg60”.   
The authors inferred form the structure that YM-254890 exerts GDI activity by an allosteric 
mechanism based on the apparent stabilization of the hinge region, Switch I and Linker I.  This 
region undergoes conformational changes associated with inter-domain opening and GDP 
release, the rate limiting step for G protein activation (18, 19). 
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FIGURE 3.3.  Universal G protein activation mechanism (adapted from (19))  
For a G protein to go from a GDP bound-inactive state (shown to the left) to a GTP bound-active 
state, it has to undergo a nucleotide free transition state (shown to the right).  This figure 
illustrates a simplified scheme of the universal mechanism that facilitates transition to the 
nucleotide free state.   In the “off” state, GDP is bound with high affinity and the GTPase domain 
and the α-helical domain are closed.  This state is maintained by the α1 helix and the α5 helix, 
which form the major structural foundation that stabilizes a network of intramolecular 
interactions.  The α1 helix and α5 helix are highlighted by grey rectangles with dashed lines (also 
marked as H1 and H5, respectively).  The boxed letters represent conserved residues that are 
vital for intramolecular interactions, and the interactions are shown by the connecting lines.  The 
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connecting lines highlight the network of interactions that maintain GDP and the α-helical 
domain to remain tightly bound.  
In the transition state, the intramolecular interactions are dispersed, which results in the α-helical 
domain to part from the GTPase domain and for GDP to release (due to low affinity 
interactions). Destabilization of the network of interactions is initiated by the α5 helix.  The α5 
helix is the conduit that transfers GPCR activation status to the G protein activation status.  A 
GPCR in the active state pulls on the α5 helix (illustrated by residues boxed in red), and causes 
α5 to undergo a disorder to order structural transition, which causes an order to disorder 
transition of the α1 helix.  The loss of the α1 helical structure results in the network of stable 
interactions to disperse.  In the allosteric inhibition model for YM/FR, YM/FR stabilizes the 
networks of intramolecular interactions and prevents GPCR imposed activation.  
The YM/FR binding site is indicated.  The residues highlighted by red circles make direct 
contact with YM/FR, whereas the residues highlighted by yellow circles do not.   Residues 
colored in red, as described in the discussion refer to R54, Y61, and F69 on Gαi1(FR).  Residues 
colored in yellow, as described in the discussion refer to T48, R52, and K270 on Gαi1(FR).   
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FIGURE 3.4.   Sequence alignment of FR binding pocket for Gαq and the analogous pocket for 
Gαi1 (adapted from (17)) 
The sequence of the FR binding pocket on Gαq is conserved but in a divergent form in Gαi1 
(17). FR contact residues that are unique to Gαq are highlighted in red, and the FR contact 
residues that are conserved in Gαq and Gαi are highlighted in yellow.  Amino acids are 
numbered according to the respective Gα subunit. Secondary structures that span the pocket are 
shown below the amino acid sequence.  The top row represents the sequence spanning α1 helix, 
Linker 1, and part of αA helix.  The bottom row represents the sequence spanning part of αF 
helix, Switch I, β2 sheet, and part of β3 sheet.  The asterisk represents the mutation site for 
R54K- Gαi1(FR).   
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FIGURE 3.5.  Spontaneous nucleotide exchange assay with BODIPY-GTPγS 
Spontaneous nucleotide exchange assay was measured by monitoring fluorescence increase 
observed upon BODIPY-GTPys binding to Gα.  At time 0, recombinant G protein was mixed 
with BODIPY-GTPγs and monitored over time.  (A) In the absence of GoLoco peptide, a GDI 
for Gαi, fluorescence increased over time.  In the presence of the GoLoco peptide, nucleotide 
exchange was inhibited in a dose dependent manner.  GoLoco peptide concentrations are colored 
coded. (B) GoLoco dose response is plotted as 100 x (maximum ΔF/Fo normalized to maximum 
ΔF/Fo of no GoLoco peptide) against Goloco peptide concentration (log M).  (C-E) Spontaneous 
nucleotide exchange was monitored for Gαi1, G αi1 (FR), and R54K-Gαi1(FR) in the presence 
or absence of FR-900359.  FR concentrations are noted to the right of the fluorescence traces. (F) 
FR dose response is plotted as 100 x (maximum ΔF/Fo normalized to maximum ΔF/Fo of no 
FR) against FR concentration (log M).   
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FIGURE 3.6.  Live cell Gαi activity reporter assay 
(A) The expression of μ-opioid receptor with an HA epitope tag on the N-terminus (HA-MOR) 
was confirmed in HEK293 cells stably expressing or transiently transfected with HA-MOR.  (B) 
The expression of internal Glutamine-Glutamine epitope tag Gαi1 (EE-Gαi1) variants in HEK293 
cells were confirmed.  Variants expressed at equivalent levels. (C) PTX treatment inhibited 
DAMGO mediated decay of cAMP production for cells expressing EE-Gαi1 but not in cells 
expressing C351G-EE-Gαi1 or C351G-EE-Gαi1(FR). Baseline cAMP levels were measured for 60 
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seconds, then stimulated for forskolin (FSK) for 300 seconds (indicated by black horizontal 
bars), finally stimulated with DAMGO for 300 seconds (indicated by grey horizontal bars).    
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Findings and Future Directions 
The overarching goal of this dissertation was to investigate mechanisms that regulate G 
protein signaling. Chapter 2 described a project that worked towards elucidating the proteasome 
degradation mechanism for RGS2, a negative regulator of G protein signaling pathways.  
Chapter 3 described the early stages of a project that aims to elucidate the molecular mechanism 
by which small molecule inhibitors YM-254890 and FR900359 inhibit G protein activation.  The 
findings and future directions are summarized below.  
 
Chapter 2: Agonist efficacy and resensitization in Gq-mediated GPCR 
signaling are regulated by proteolytic degradation of Regulator of G 
Protein Signaling 2 
The goals of this part of the dissertation were twofold: 1) To gain a better understanding 
of the RGS2 degradation mechanism, and 2) determine how proteasome degradation of RGS2 
regulates GPCR signaling.  
The RGS2 degradation mechanism – This project was motivated by key observations that 
1) demonstrated RGS2 degradation is dependent on the proteasome,  and 2) implicated the N-
terminus of RGS2 as a signal for a proteasome dependent degradation pathway (1).  Over the 
course of this project, several groups had reported their findings on the degradation mechanism 
for RGS2 (2–6) (Figure 4.1).  The observations and proposed mechanisms from these studies, 
however, contradict or are unrelated to one another, and they have yet to be consolidated into a 
consensus mechanism.  The discrepancies are described below in an abbreviated summary.  
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One of the first hypotheses for the RGS2 degradation mechanism was that RGS2 is 
degraded by the N-end rule pathway.  This was based on the observation that the N-terminus of 
RGS2 contains a residue at position 2 that is predicted to be a substrate for the N-end rule 
pathway (1, 7). Supporting evidence for this model was reported in a study by Park, S. et al., 
which demonstrated that RGS2 is degraded by a variant of the N-end rule pathway, called the 
Ac/N-end rule pathway (5).  This model is challenged by a study by Sjörgen, B. et al., which 
found that a key enzyme of the N-end rule pathway (arginine transferase) is not required for 
RGS2 degradation (4).  Furthermore, they found that RGS2 degradation is dependent on the 
Cullin4B-DDB1-FBXO44 E3 ubiquitin ligase complex, which is not related to the N-end rule 
pathway.  Although these observations do not rule out the N-end rule hypothesis, they suggest 
additional degradation mechanisms may be involved.   
Signaling pathways have also been implicated in RGS2 degradation.  For example, RGS2 
protein levels are stabilized by cardiac glycosides (3, 6), PKC activators (8), and a cGMP 
dependent protein kinase inhibitor (2).  However, the mechanistic underpinnings of RGS2 
stabilization by these signaling pathways remain unclear.   
The observations from this dissertation provide a potential opportunity to further expand 
and perhaps clarify our understanding of the RGS2 degradation mechanism.  The comprehensive 
analysis of the RGS2 N-terminal domain, as described in this dissertation, revealed a novel 
bipartite hydrophobic motif required for degradation.  Intriguingly, these signals were not 
required for interaction with TEB4 or CUL4B, the two reported E3 ligases for RGS2 (4, 5).  This 
suggests the bipartite signal may be utilized by additional degradation mechanisms.  From these 
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observations, alternative hypotheses for the mechanism of RGS2 degradation were generated and 
are described below.   
Hypothesis 1 – Additional E3 ligases or substrate recognition elements are required for 
RGS2 degradation (Figure 4.2).  This hypothesis is based on observations that the Doa10 E3 
ligase, the yeast homolog of  TEB4,  requires additional components for substrate recognition 
and ubiquitination such as heat shock proteins and specific E2 conjugating enzymes (9, 10).  
This model predicts that the acetylated N-terminus is sufficient for RGS2 to interact with TEB4, 
but additional components are required to form a functionally competent RGS2-TEB4 complex 
to polyubiquitinate RGS2.  One strategy to identify additional components is to use the 
hydrophobic motif of RGS2 as bait to trap interacting proteins.   
Hypothesis 2 – TEB4 and CUL4B-DDB1-FBXO44 are indirect regulators of RGS2 
stability.  This hypothesis is based on two observations 1) hydrophobic motifs are not required 
for interaction with TEB4 and CUL4B, and 2) the role of CUL4B-DDB1-FBXO44 as the RGS2 
E3 ligase was suggested by siRNA mediated knockdown experiments (4).  Therefore, it cannot 
be ruled out that RGS2 stabilization was caused by pleiotropic effects of siRNA knockdown.   
One strategy to identify mechanisms that directly regulate RGS2 stability is to screen for genetic 
deletions that rescue the RGS2 stabilization phenotype observed in TEB4 and CUL4B-DDB1-
FBXO44 knockout cells.  This may aid in resolving protein degradation networks that control 
RGS2 stability, and potentially aid in identifying E3 ligases that directly regulate RGS2.    
Hypothesis 3 – Hydrophobic motifs required for RGS2 degradation are used for steps 
subsequent to polyubiquitination by E3 ligase(s), such as recognition and/or efficient substrate 
processing by the 26S proteasome (Figure 4.3).   Studies have shown that unfolded or disordered 
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domains facilitate efficient initiation of substrate degradation (11, 12), for it is thought that the 
structural properties (or lack thereof) of unfolded or disordered regions allow the substrate to be 
threaded through the narrow channel of the 20S proteasome.  Perhaps the hydrophobic motifs of 
RGS2 confer the N-terminus to adopt a disordered or misfolded state to facilitate efficient 
processing by the 26S proteasome.   
Overall, this part of the dissertation characterized intrinsic signals that drive degradation 
of RGS2 and has served to generate new hypotheses for alternative mechanisms.  Testing these 
hypotheses should expand our understanding of the RS2 degradation mechanism.  
GPCR regulation by proteasome degradation of RGS2 – This dissertation also 
characterized aspects of GPCR activity that are modulated by proteasome degradation of RGS2.  
Prior studies provided inferential evidence that RGS2 turnover impacts GPCR activity (1, 5).  
This dissertation demonstrated for the first time that proteasome mediated degradation of RGS2 
directly regulates GPCR signaling by controlling agonist efficacy and recovery of agonist 
responsiveness (receptor resensitization).  A particularly striking observation was that the 
temporal regulation of GPCR activity corresponded to the protein half-life of RGS2, indicating 
that proteasome degradation of RGS2 is a crucial cellular process that underlies kinetic 
regulation of GPCR activity.  
These experiments were performed in a transfected cell culture system where cellular 
states were manipulated with drug treatment. Therefore, follow up studies are required to truly 
understand the network of regulatory mechanisms that control expression levels of endogenous 
RGS2.  Elucidation of these processes could provide insight into the molecular basis of 
pathogenesis by disease associated mutations like RGS2(Q2L) (Figure 4.4) (1, 14).   
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Drawing on observations reported in this dissertation and numerous other studies, here 
we propose a model for dynamic regulation of RGS2 expression in vivo (Figure 4.4).  This model 
predicts that RGS2 expression is controlled by the antagonistic actions of transcriptional 
regulation and proteasome mediated degradation of RGS2.  In many cell and tissue types,  RGS2 
mRNA is upregulated in response to various  GPCR agonists (18).  The induction of RGS2 
mRNA is rapid and peaks within 30 minutes to an hour, and this is thought to serve as a negative 
feedback mechanism that restricts amplitude and duration of Gs and Gq signaling responses (19–
21).  Proteasome degradation of RGS2, on the other hand, likely interdicts this negative feedback 
mechanism.  This will relieve inhibition of GPCR activity and allow for subsequent rounds of 
agonist evoked receptor activation.   
The sum of the two processes, transcriptional regulation and proteasome degradation, 
will likely have two consequences: 1) RGS2 expression levels will be restricted within a narrow 
window, and 2) RGS2 will exhibit a pulsatile pattern of expression.  Consequently, the amplitude 
and duration of GPCR signaling responses will be restricted within a range that allows for 
appropriate cellular and physiological responses.   
For a patient with a disease associated allele like RGS2(Q2L), the accelerated 
degradation rate of RGS2(Q2L) may cause GPCR signaling responses to surpass a “pathogenic 
threshold’ and result in activation of cellular processes that drive disease states.  In this case,  
targeting the RGS2 degradation pathway may serve as a potential therapeutic avenue for treating 
diseases linked to partial loss of RGS2 expression or function such as hypertension and anxiety 
(13–17).  Follow up studies that test this model should expand our understanding of the network 
of regulatory mechanisms that control RGS2 expression and regulation of GPCR activity.    
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Chapter 3:  Investigation of the GDI Mechanism for YM-254890 and 
FR900359 
This part of the dissertation presented preliminary work towards characterization of the 
allosteric inhibition mechanism of YM-254890 and FR900359.   
A key observation from this preliminary result was that the chimeric protein Gαi1(FR) 
(Gαi1 containing YM/FR binding sites on Gq/11) exhibited sensitivity to FR.  This indicated that 
FR selectivity to Gq/11 is due solely to the unique binding sites, and furthermore, this suggested 
that FR inhibits GDP release by an allosteric mechanism.  Going forward, the use of the 
Gαi1(FR) chimeric protein should aid in fully testing this allosteric model of inhibition by 
performing the follow-up experiments outlined in the Discussion Section of Chapter 3.   
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FIGURES 
 
FIGURE 4.1.  Pathways implicated in RGS2 degradation 
A number of studies have described E3 ligases and signaling pathways involved in RGS2 
degradation.  The first column lists observations that support the Ac/N-end rule model of 
degradation.  Knockdown of N-terminal acetylase (Naa60) or TEB4 E3 ligase stabilized RGS2.  
The middle column lists observations that refute the N-end rule model of degradation.  
Knockdown of arginine transferase (ATE1), a key enzyme in the N-end rule pathway, had no 
effect on RGS2 stability.  RGS2(Q2R) is a disease associated mutant that is predicted to be 
unstable because arginine at position 2 is a potent substrate of the N-end rule pathway.  
However, in one study, the stability of RGS2(Q2R) was comparable to wildtype RGS2.  The 
right most column lists pathways unrelated to the N-end rule pathway that are involved in RGS2 
degradation.  Knockdown of CUL4B-DDB1-FBXO44 E3 ligase complex stabilized RGS2.  
Cardiac glycosides, PKC activators, and a NO-cGMP kinase inhibitor stabilized RGS2.  The 
directions of arrows represent the observed effect on RGS2 stability. Superscripts represent the 
references in which the observations were reported.   
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FIGURE 4.2.  Model for hypothesis 1 – hydrophobic motif recruits additional components 
In this model, the acetylated N-terminus of RGS2 (drawn as a rectangle marked “RGS2” flanked 
by an acetylated N-terminus) is necessary for interaction with TEB4 (drawn as a 13-pass 
transmembrane protein on the ER membrane bilayer) but is not sufficient for polyubiquitination 
of RGS2.  Complete polyubiquitination requires additional degradation components (drawn as a 
green oval marked “E2/HSP”).  This hypothesis is based on the substrate degradation mechanism 
of Doa10, the yeast homolog of TEB4, which requires additional components like heat shock 
proteins (HSP) and E2 conjugating enzymes (E2) to degrade certain substrates.  Like Doa10, 
TEB4 also may require additional components to polyubiquitinate and degrade RGS2, 
specifically in a manner dependent on the hydrophobic motifs in the RGS2 N-terminal domain.   
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FIGURE 4.3.  Model for hypothesis 3 – hydrophobic motifs involved in steps subsequent to 
polyubiquitination (adapted from (12)) 
In this model, the hydrophobic motifs in the N-terminus of RGS2 function as degradation 
initiation sites that allow for efficient and robust proteolysis by the 26S proteasome.  This 
hypothesis is based on an emerging concept that certain substrates of the ubiquitin proteasome 
pathway may be targeted for degradation through multiple tiers of degradation signals (12).  The 
authors of this study assert that the first-tier signal is the E3 ligase recognition motif.  The 
second-tier signal is the E3 ligase catalyzed-polyubiquitin chain, which is a signal sequence that 
is recognized by the 26S proteasome.  The third-tier signal is a degradation initiation site, which 
typically assumes the form of a disordered or unfolded region.  It is thought that the disordered 
or unfolded state allows for the substrate to be efficiently threaded into the narrow channel of the 
20S proteasome.  The tiers of degradation signals are illustrated and numbered at the top of the 
figure.  The yellow patch represents the E3 recognition motif, the orange circles represent 
ubiquitin molecules, and the red sinuous line represents the degradation initiation site.   
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FIGURE 4.4.  Model of dynamic RGS2 expression by transcriptional regulation and proteasome 
degradation 
In cells and tissues, RGS2 levels are likely to oscillate due to the antagonistic processes of 
transcriptional upregulation and proteasome degradation.  This oscillation is illustrated above, 
where RGS2 levels rise in response to agonist stimulation, and RGS2 levels decline rapidly due 
to constitutive degradation by the proteasome.  These antagonistic processes are likely to restrict 
RGS2 expression levels such that GPCR responses are maintained within a healthy window (the 
theoretical boundaries of a “healthy” GPCR response are illustrated above as dashed horizontal 
lines).  This model predicts that for patients with the disease associated mutant RGS2(Q2L), 
accelerated degradation of RGS2 may result in overall reduced RGS2 expression and 
consequently result in a GPCR response that surpasses the “pathogenic threshold” to stimulate 
signaling pathways that give rise to disease states.    
